Document:

License Agreement

 Exhibit 10.35 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested

 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 203.406 
 LICENSE AGREEMENT 

This License Agreement (the “Agreement”), made and effective as of June 28, 2010 (the “Effective Date”), by and between
E. I. du Pont de Nemours and Company, a Delaware corporation having its principal place of business at 1007 Market Street, Wilmington, Delaware 19898 (“DuPont”) and Bioamber S.A.S., a French corporation having its principal place of
business at Route de Bazancourt, F-51110, Pomacle France (“Bioamber”). In this Agreement DuPont and Bioamber shall also be referred to individually as a “Party” and collectively as the “Parties.” 

RECITALS 
 WHEREAS,
DuPont is has certain rights in certain U.S. patents, which patents are [***], pertaining to the [***] to produce 1,4 butanediol (“BDO”) and tetrahydrofuran (“THF”). 

WHEREAS, DuPont is the owner of the Licensed Intellectual Property (as defined below); 
 WHEREAS, Bioamber is in the business of manufacturing succinic acid and derivative products used in a variety of applications; and 
 WHEREAS, Bioamber desires to obtain a sublicense under the aforementioned patents and a license to the Licensed Intellectual Property, all to produce BDO and THF from succinic acid according to the terms
hereof, and DuPont is willing to grant such sublicense and rights to Bioamber. 
 NOW, THEREFORE, in accordance with the foregoing recitals and
the rights and obligations specified herein, and for good and valuable consideration, the receipt of which is hereby recognized, DuPont and Bioamber agree as follows: 
  

	1.	DEFINITIONS 

 1.1. “Affiliate”
means any corporation, firm, limited liability company, partnership or other entity that directly or indirectly Controls or is Controlled by or is under common Control with a Party to this Agreement, for so long as such Control-based relationship
exists. 
 1.2. “Catalysts” mean those catalysts claimed in the Sublicensed Patents. 

1.3. “Confidential Information” means information disclosed by a Disclosing Party hereunder when such is identified as the confidential
information of the Disclosing Party. Tangible embodiments of information shall be deemed as “identified as confidential information” if clearly labeled as “Confidential” or “Proprietary” or with some other legend or
marking indicating the confidential nature of the information. Information that is disclosed verbally or by other non-tangible disclosure to the Receiving Party shall be deemed as “identified as confidential information” if it is set forth
by the Disclosing Party in a writing clearly labeled “Confidential” or “Proprietary” or with some other legend or marking indicating the confidential nature of the information, and the writing is delivered to the Receiving Party
within fifteen (15) days of said verbal/non-written disclosure. Information disclosed verbally or by other non-written disclosure to the Receiving Party shall be treated as Confidential Information during the fifteen (15) day period
following such disclosure. 

  
 1 

* Confidential treatment requested 

 1.3.1. Information shall not be considered Confidential Information to the extent that any
such information was (a) as of the date of disclosure to the Receiving Party, known to the Receiving Party and such knowledge can be substantiated by reasonable documentation; (b) as of the date of disclosure to the Receiving Party,
disclosed in published literature or generally available to the public; (c) after the date of disclosure to the Receiving Party, disclosed in published literature or generally available to the public, other than by a breach by the Receiving
Party of the obligations of confidentiality and non-use set forth in this Agreement; (d) developed by the Receiving Party independently from, and without exposure to, the information provided by the Disclosing Party; or (e) obtained by the
Receiving Party from a third party without binder of secrecy, provided that such third party had no obligation of confidentiality to the Disclosing Party or any of its Affiliates relating to the Confidential Information. 

1.3.2. Information disclosed hereunder shall not be deemed to be within the exceptions merely set forth in Section 1.3.1 merely
because such information is embraced by more general knowledge in the public domain or in the Receiving Party’s possession. In addition, no combination of features shall be deemed to be within the foregoing exceptions merely because individual
features are in the public domain or in the Receiving Party’s possession, but only if the combination itself and its principles of operation are in the public domain or in the Receiving Party’s possession. 

1.3.3. For the purposes of Sections 1.3 through 1.3.3, inclusive, “information” includes, without limitation, all information
relating to existing and potential inventions (whether or not reduced to practice), discoveries, know-how, technologies, reports, data, results, observations, computer programs, patent applications, hypotheses, research directions, developments,
improvements, drawings, designs, specifications, methodologies, algorithms, formulas, protocols, strategic plans, business plans, business opportunities, draft and/or final regulatory filings, customers, potential customers, suppliers, markets,
contracts, prices, products, personnel, strategies, policies, systems, procedures, information, processes, research, applications, methods of manufacture and any other information relating to the Disclosing Party or any of its Affiliates.

 1.4. “Commercial Field” means the manufacture of Hydrogenation Products and the use, selling or otherwise transferring, offering
for sale, and/or exporting of such Hydrogenation Products. 
 1.5. “Control” means ownership, directly or through one or more
Affiliates, of fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign entity in a particular jurisdiction) or more of the shares of stock entitled to vote for the election of directors in the case
of a corporation, or fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign entity in a particular jurisdiction) or more of the equity interests in the case of any other type of legal entity, or
status as a general partner in any partnership, or any other arrangement whereby a Party controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity. 

1.6. “Delayed Rights Date” [***]. 

  
 2 

* Confidential treatment requested 

 1.7. “Development Period” means the period commencing on the Effective Date and ending on the
earlier of (a) the [***] year anniversary of the Effective Date, and (b) the date on which DuPont receives a written notice from Bioamber indicating that the Development Period has ended and Bioamber’s right of termination
pursuant to Section 6.2 has terminated, provided that in no event shall the Development Period end prior to the Delayed Rights Date. 
 1.8. “Disclosing Party” means a Party disclosing its Confidential Information to a Receiving Party hereunder. 
 1.9. “DuPont Background Technology” means all inventions, know-how, technology, or other information related to the [***] as of the Effective Date. 

1.10. “DuPont Indemnitees” means DuPont and its directors, officers, agents, employees, contractors, and representatives; DuPont’s
Affiliates and their directors, officers, agents, employees, contractors, and representatives of DuPont’s Affiliates; and the successors, heirs and assigns of any of the foregoing. 
 1.11. “Exclusion Period” means the [***] year period commencing on the Effective Date and ending on the [***] year anniversary of the Effective Date. 

1.12. “Hydrogenation” means the process of hydrogenating succinic acid as claimed in the Sublicensed Patents. 

1.13. “Hydrogenation Products” means [***]. 
 1.14. “Improvements” means all inventions, know-how, technology, or other information discovered or developed by or for Bioamber during the Term related to the Sublicensed Patents to the extent
that such inventions, know-how, technology, or other information is not incorporated in the DuPont Background Technology. 
  

	1.15.	[***] 

 1.16. “Licensed Intellectual
Property” means the information in the Technical Reports and the Technical Know-how. 
 1.17. “Patent Challenge” means a
challenge to the validity, patentability, enforceability and/or non-infringement of any of the Sublicensed Patents or otherwise opposing any of the Sublicensed Patents. 

 

	1.18.	[***] 

 1.19. “Receiving
Party” means a Party receiving Confidential Information from the Disclosing Party hereunder. 
 1.20. “Representatives” means the
directors, officers, employees, agents, contractors, and/or Affiliates of a Receiving Party to whom the Receiving Party needs to disclose Confidential Information in connection with the Parties’ performance under this Agreement. 

1.21. “Research Field” means making research and development quantities of Hydrogenation Products and using such Hydrogenation Products for
one’s own internal research purposes. For the purposes of this Agreement “research and development quantities” includes such amounts as would be used or produced in laboratory scale research projects, but does not include amounts used
or produced in pilot study projects. 
 1.22. “Sublicensed Patents” means the [***] and listed in Schedule A. 

  
 3 

* Confidential treatment requested 

 1.23. “Technical Know-how” means the information in the responses to any consulting questionnaires
provided pursuant to Section 2.9.1. 
 1.24. “Technical Reports” means the documents listed in Schedule B. 

1.25. “Term” means the period starting on the Effective Date and ending on the [***] anniversary of the Effective Date. 

1.26. “Third Party” means an entity other than DuPont or Bioamber. Third Parties include, without limitation, the Affiliates of the Parties.

  

	2.	SUBLICENSE GRANT 

 2.1. Grant.

 2.1.1. DuPont hereby grants the following rights to Bioamber solely within the Research Field: (a) a non-exclusive,
worldwide sublicense, under the Sublicensed Patents to perform Hydrogenation, and (b) a non-exclusive, worldwide license, under the Licensed Intellectual Property to perform Hydrogenation. The sublicense and license granted in this
Section 2.1.1 shall be effective as of the Effective Date. 
 2.1.2. DuPont hereby grants the following rights to Bioamber
solely within the Commercial Field: (a) a non-exclusive, worldwide sublicense, under the Sublicensed Patents to perform Hydrogenation, and (b) a non-exclusive, worldwide license, under the Licensed Intellectual Property to perform
Hydrogenation. The sublicense and license granted in this Section 2.1.2 shall be effective as of the Delayed Rights Date, provided that on the Delayed Rights Date Bioamber is in compliance with all the terms and conditions of this Agreement.

 2.2. Sublicensing Rights. 
 2.2.1. As of the end of the Development Period, Bioamber shall have the right to sublicense the rights granted pursuant to Section 2.1.1 and/or 2.1.2 to Third Parties, subject to DuPont having
the right to reject any potential sublicensee, and provided that any such Third Party agrees to abide by all the terms of this Agreement as they apply to Bioamber as a rights grantee hereunder. Bioamber shall grant no sublicenses during the
Development Period other than sublicenses of the rights granted pursuant to Section 2.1.1 to allow Third Parties to assist Bioamber with the further development pursuant to Section 2.12.2. 

a. Prior to the granting of any such sublicense, Bioamber will provide DuPont a written notice identifying the potential Third Party that
Bioamber desires to sublicense and the scope of the rights Bioamber desires to sublicense to such Third Party. 
 b. DuPont shall
have thirty (30) days from the receipt of such notice to provide a written notice to Bioamber rejecting such Third Party as a sublicensee. Failure by DuPont to provide such notice to Bioamber within the above-noted thirty (30) day period
shall be deemed as DuPont having waived its right to reject such potential sublicensee to be granted rights of the scope set forth in the notice. 
 c. DuPont agrees to not exercise its right of rejection in a commercially unreasonable manner, and DuPont agrees not to reject a proposed sublicensee

  
 4 

* Confidential treatment requested 

 
solely on the grounds that it is a competitor of DuPont. The fact that DuPont has rejected or failed to reject any potential sublicensee shall create no obligation on DuPont with respect to its
right of rejection with respect to any other potential sublicensee presented by Bioamber. 
 d. In the event that DuPont fails to
exercise its right of rejection hereunder and, DuPont shall incur no liability for the actions of Bioamber or any sublicensee as a result of DuPont allowing Bioamber to sub-license the rights granted pursuant to Section 2.1.1 and/or 2.1.2 to
any Third Party, and Bioamber hereby indemnifies and hold DuPont harmless in the event of any such claim. 
 2.2.2. Provided that
this Agreement is not terminated pursuant to any of Sections 6.2, 6.3.1, 6.3.2, 6.4, and or 6.5 through 6.5.2, inclusive, DuPont agrees that it shall grant a license granting such Third Party sublicensee the rights granted pursuant to
Section 2.1.1 and/or 2.1.2 to those Third Parties having a valid sublicense to the rights granted pursuant to Section 2.1.1 and/or 2.1.2 on the date this Agreement is so terminated, provided that any such Third Party sublicensee(s)
is not then in default under the terms of the sublicense agreement between the Third Party and Bioamber and further provided that DuPont shall be under no obligation to grant any such license in the event that so doing would violate any law
or legal or governmental regulation. The financial terms of such license between DuPont and the Third Party shall be the same as those set forth in the sublicense agreement then in effect between the Third Party and Bioamber. The license agreement
between DuPont and such Third Party shall obligate such Third Party to immediately pay to DuPont any amount in arrears under the sublicensee agreement between the Third Party and Bioamber and shall obligate such Third Party to abide by all the terms
of this Agreement as they apply to Bioamber as a rights grantee hereunder. DuPont’s obligations under this Section shall not apply to any sublicense granted during the Development Period. Other than the granting of a license as described above,
DuPont shall have no affirmative to take any action that Bioamber may have had in the sublicense agreement between the Third Party and Bioamber, including without limitation the obligation to provide any training, rights to improvements, technical
services, etc.). 
 2.2.3. Bioamber shall promptly notify DuPont of the identity of any Third Party to which it has sub-licensed
the rights granted pursuant to Section 2.1.1 and/or 2.1.2. 
 2.3. License Restrictions and Limitations. 

2.3.1. The Parties each agree that the rights granted pursuant to Section 2.1.1 do not include any rights to use or make the
Catalysts, other than for the performance of Hydrogenation in the Research Field. 
 2.3.2. The Parties each agree that the
rights granted pursuant to this Section 2.1.2 do not include any rights to use, manufacture, offer for sale, sell, or export the Catalysts, other than for the performance of Hydrogenation in the Commercial Field. 

2.3.3. The Parties each agree that Bioamber shall make no use of the Catalysts, other than for the performance of Hydrogenation in the
Research Field or for the performance of Hydrogenation in the Commercial Field, as licensed hereunder 
 2.3.4. The Parties each
agree that the Licensed Intellectual Property contains no information concerning the production or use of [***]. The Parties each agree that the 

  
 5 

* Confidential treatment requested 

 
rights granted pursuant to Sections 2.1.1 and/or 2.1.2 do not include any rights to produce [***]. This Section, however, shall not be construed to restrict Bioamber or its customers from
using for any purpose the Hydrogenation Products made or produced pursuant to this Agreement. . 
 2.3.5. The Parties each
agree that Bioamber shall make no use of the rights granted pursuant to Sections 2.1.1 and/or 2.1.2 and or the Licensed Intellectual Property to produce or use [***]. 
 2.3.6. The Parties each agree that Bioamber shall not make any use of the Licensed Intellectual Property outside the scope of the rights granted in Sections 2.1.1 and 2.1.2. 

2.3.7. The Parties each agree that DuPont has made no representation that the Licensed Intellectual Property contains information
concerning the production or use of [***] or that the rights granted in Sections 2.1.1 and 2.1.2 will allow Bioamber to make any use of the Licensed Intellectual Property outside the scope of the rights granted in Sections 2.1.1 and 2.1.2 or
to produce [***]. 
 2.4. Commercial Benefits. The Parties each agree that the benefits accruing to Bioamber pursuant to this
Agreement are not limited to the rights granted pursuant to Sections 2.1.1 and 2.1.2 under the Sublicensed Patents. The Parties each agree that as a primary consideration Bioamber receives additional commercial benefits, including, without
limitation, benefits from having access to the Licensed Intellectual Property as allowed hereunder, the reduction or abatement of research expenses that Bioamber would incur absent to access to the Licensed Intellectual Property, the forbearance
obligations on DuPont (as set forth in Sections 2.7.1 through 2.7.1.b, inclusive, and being able to perform Hydrogenation, as licensed hereunder, earlier in time than Bioamber would have been able to do absent the access to the Licensed Intellectual
Property as allowed hereunder. 
 2.5. No Implied Licenses. There are no rights or licenses implied for either Party to practice the
Confidential Information and/or intellectual property of the other Party and /or any Third Party, except as expressly provided and granted in this Agreement. 
 2.6. Owners of the Sublicensed Patents. 
 2.6.1. Bioamber acknowledges that
neither DuPont nor any Affiliate of DuPont can in any way restrict [***]. Nothing in this Agreement shall create for DuPont or any of its Affiliates any obligation to restrict or attempt to restrict [***]. Nothing in this Agreement
shall create for Bioamber any remedy in the event [***] in a manner that is contrary to the interests of Bioamber. 

2.6.2. As neither DuPont nor any Affiliate of DuPont is the owner of the Sublicensed Patents, the Parties agree that neither DuPont nor
any Affiliate of DuPont is under any obligation to prosecute, maintain, or otherwise keep the Sublicensed Patents in force, or enforce the Sublicensed Patents against any Third Party or to require any Third Party to do any of the same. Nothing in
this Agreement shall create for Bioamber any remedy in the event [***] fails to prosecute, maintain, or otherwise keep the [***] in force, or enforce the [***] against any Third Party, even if the results of such failure by
[***] are contrary to the interests of Bioamber. 
 2.6.3. Neither DuPont nor any Affiliate of DuPont is under any
obligation to do any of the following (a) seek, prosecute, maintain, or otherwise keep any intellectual property 

  
 6 

* Confidential treatment requested 

 
right in the Licensed Intellectual Property or (b) enforce any intellectual property right in the Licensed Intellectual Property against any Third Party or (c) require any Third Party
to do (a) or (b) above. Nothing in this Agreement shall create for Bioamber any remedy in the event DuPont fails to do (a), (b), and/or (c) above. 
 2.6.4. Nothing in this Agreement shall create for Bioamber any remedy in the event [***] performs, or fails to perform, any act, even if the results of such performance/non-performance are contrary
to the interests of Bioamber. Without limiting the foregoing, nothing in this Agreement shall create for Bioamber any remedy in the event [***] publishes any portion of the [***]. 

2.7. Exclusivity with Respect to DuPont. 
 2.7.1. During the Exclusion Period and so long as Bioamber has not breached any material provision of this Agreement, DuPont shall not do any of the following: 

a. grant to any Third Party a sublicense to any of the rights granted Bioamber pursuant to Sections 2.1 through 2.2.1.d, inclusive, or

 b. to the extent DuPont may so forebear without violating an obligation to a Third Party (such Third Parties to include
without limitation, [***]), share the contents of any of the Licensed Intellectual Property with Third Parties, other than as required for DuPont to practice on its own behalf, as permitted under this Agreement. 

2.7.2. It shall not be considered a breach of DuPont’s forbearance obligations set forth in this Agreement, nor shall Bioamber or any
of its sublicensees gain any remedy, if DuPont shares the contents of the Licensed Intellectual Property in response to a request by any legal or regulatory authority to do so, or in any legal action or proceeding. 

2.7.3. For so long as this Agreement is in effect, absent the express written permission of Bioamber, DuPont shall not [***].
Nothing in this Agreement shall be interpreted as limiting DuPont’s right to [***]. 
 2.8. Technical Reports. Within ten
(10) days of the Effective Date, DuPont shall provide the Technical Reports to Bioamber. 
 2.9. Technical Know-how. DuPont shall
provide Technical Know-how to Bioamber to clarify the technical information concerning Hydrogenation and the Technical Reports licensed pursuant to Section 2.1.1 and 2.1.2, as follows: 

2.9.1. DuPont shall expend up to [***] person-days, tallied in [***] increments, making a good faith effort to provide
answers to questionnaires submitted by Bioamber during the first twelve (12) months after the Effective Date, provided that  
 a. such responses do not require DuPont to violate an obligation it has to any Third Party (such Third Parties to include without limitation, [***]) with respect to information Bioamber desires to
be included in such response, and 
 b. nothing in this Agreement obligates DuPont to perform any searches of external records or
perform any experimental work or perform any other act than a review of its readily available internal records to provide a response to the questionnaires. 

  
 7 

* Confidential treatment requested 

 2.9.2. During the [***] years following the Effective Date, at Bioamber’s
request, DuPont may expend efforts preparing written responses to questionnaires submitted by Bioamber after the twelve (12) month anniversary of the Effective Date and/or requiring the expenditure of effort by DuPont in addition to the
[***] person-days set forth in Section 2.9.1 at DuPont’s sole discretion, such additional effort to be provided, if DuPont decides to so provide, at a cost to Bioamber of [***] per day, billed in [***] increments.
DuPont shall invoice Bioamber for any fees or expenses incurred pursuant to this Section. 
 2.10. [***] Suppliers. During the
first [***] of the Term, DuPont shall provide to Bioamber (a) manufacturing protocols for [***], (b) a list of the Third Parties that manufacture [***], and (c) [***]. 

2.11. Provision of [***] to DuPont. Bioamber agrees that it will, at DuPont’s request, negotiate in good faith with DuPont
concerning entering into an agreement with DuPont regarding [***]. Any agreement resulting from such negotiations will obligate Bioamber to [***]. 
 2.12. Improvements. 
 2.12.1. DuPont shall be under no obligation to make
any further development or improvement to, in connection with, the Licensed Intellectual Property. 
 2.12.2. The rights granted
pursuant to Sections 2.1.1 and/or 2.1.2 includes the right for Bioamber to further develop the inventions claimed in the Sublicensed Patents and Licensed Intellectual Property within the scope of the license rights granted in Sections 2.1.1 and/or
2.1.2. Such development shall be directed, namely and without limitation, towards methods of manufacturing Hydrogenation Products using a biobased succinic acid feedstock. 
 2.12.3. As part of such further development, Bioamber will test the Catalysts with succinic acid derived from Bioamber’s fermentation broth and proprietary downstream purification process. Bioamber
will communicate the results of such evaluations to DuPont, which results shall be considered as Confidential Information of Bioamber. 
 2.12.4. The Parties acknowledge and agree that [***]. 
 2.12.5. Bioamber
shall have the right at its own discretion to secure intellectual property protection in any of the Improvements at its own expense. 
 2.12.6. Bioamber shall report all Improvements to DuPont promptly after the creation of such Improvement. 
 2.12.7. Bioamber shall provide DuPont with a semi-annual summary report regarding any further evaluations of, development in, or improvement to, the Licensed Intellectual Property. Such reports will
include any Improvements made by Bioamber. Such reports will be sent to DuPont at the address set forth in Section 8.1. 
  

	2.13.	[***]. 

  

	2.14.	[***]. 

 2.14.1.
[***]. 
 2.14.2. [***]. 

  
 8 

* Confidential treatment requested 

	3.	PAYMENTS 

 3.1. Initial Payment.
Bioamber shall make a lump-sum payment to DuPont of [***], within ten (10) days following the Effective Date, which payment shall not be creditable or refundable in any event. 
 3.2. Royalties. In further consideration of the non-exclusive rights granted in Sections 2.1 through 2.2.3, , inclusive, and the commercial benefits afforded Bioamber thereby, as noted in
Section 2.4, Bioamber shall pay DuPont the following amounts, subject to Section 3.4.2 
 3.2.1. [***]
percent [***] of all consideration received by Bioamber, including without limitation, [***]; and 
 3.2.2.
[***] percent [***] of net sales of [***], less (a) [***] invoiced to the Third Party transferee of [***] and (b) [***] and (c) [***], all as determined according to standard accounting
practices. 
 3.2.3. Notwithstanding the foregoing, no royalty will be paid on Bioamber sales of [***] to DuPont from
Bioamber that [***]. 
 3.3. Minimum Royalties. The following minimum annual royalty payments shall be paid by Bioamber to DuPont
to maintain the non-exclusive rights granted in Sections 2.1 through 2.2.3, inclusive: 
 3.3.1. Subject to Section 3.4.2,
within thirty (30) days following the first anniversary of the Effective Date, Bioamber will pay DuPont a minimum royalty of [***], less any amount paid by Bioamber to DuPont pursuant to Sections 3.2 through 3.2.2, inclusive, during the
twelve (12) months preceding the first anniversary of the Effective Date. 
 3.3.2. Within thirty (30) days following
the second anniversary of the Effective Date and each subsequent anniversary of the Effective Date thereafter, subject to Section 5.4, Bioamber will pay DuPont a minimum royalty of [***], less any amount paid by Bioamber to DuPont
pursuant to Sections 3.2 through 3.2.2, inclusive, during the twelve (12) months preceding the relevant anniversary of the Effective Date. 

3.4. Infringement Claims by Third Parties. 
 3.4.1. If the practice of the license rights granted pursuant to this Agreement results in a Third Party bringing a claim, suit or proceeding alleging patent infringement against Bioamber, Bioamber shall
promptly notify DuPont in writing setting forth the facts of such claim in reasonable detail. 
 3.4.2. Royalty Abatement.
If it is impossible for Bioamber to practice the rights granted pursuant to Sections 2.1.1 and/or 2.1.2 without obtaining a license from the Third Party asserting an infringement claim pursuant to Section 3.4 and Bioamber takes a license
directly from the party alleging infringement, DuPont shall [***] set forth in Sections 3.2.1 and/or 3.2.2 and [***] set forth in Section 3.3.1 and 3.3.2 by an amount equal to [***] percent [***] of the royalties
[***], provided that in no event shall the [***] set forth immediately above be [***]. 
 3.5. Invoices for Additional
Technical Know-how. If DuPont expends any effort providing Technical Know-how to Bioamber pursuant to Section 2.9.2, Bioamber shall pay invoices from DuPont for such efforts within thirty (30) days of Bioamber’s receipt thereof.

  
 9 

* Confidential treatment requested 

 3.6. Payment Period. 
 3.6.1. Bioamber and DuPont each understands and agrees as follows: 
 a. all the
Sublicensed Patents are set to expire prior to the end of the Term; 
 b. the Sublicensed Patents could each be abandoned or be
held invalid or unenforceable at any time prior to their scheduled expiration date; 
 c. and the Licensed Intellectual Property
could become part of the public domain as a result of the actions of [***] or any Third Party to whom [***] has provided the Licensed Intellectual Property; and 
 d. the Parties have established the payment schedules set forth in this Agreement as a method of amortizing the financial consideration to be provided by Bioamber in return for the timeliness of benefits
accruing to Bioamber hereunder, such benefits to include without limitation, the rights granted pursuant to Sections 2.1.1 and 2.1.2 and the commercial benefits set forth in Section 2.4. 

3.6.2. As a result of the forgoing, the Parties each agree that Bioamber’s obligation to pay royalties and minimum royalties to
DuPont as set forth in Sections 3.2 through 3.3.2, inclusive, shall continue through the Term, regardless of the status of the Sublicensed Patents or of the Licensed Intellectual Property, unless this Agreement is terminated pursuant to
Section 6.2 or 6.3.3, in which case Bioamber’s obligation to pay royalties and minimum royalties to DuPont as set forth in Sections 3.2 through 3.3.2, inclusive, shall terminate at the date of termination of this Agreement. 

3.7. Reports. Subsequent to the lump sum payment pursuant to Section 3.1, Bioamber shall report in writing to DuPont, within thirty
(30) days after the end of each anniversary date of the Effective Date, the royalty payments and net sales of Hydrogenation Products subject to royalty payments pursuant to Article 3 during the prior twelve (12) month period. If there were
no such royalties or sales, a report nevertheless shall be submitted so stating. Payment shall be submitted to DuPont concurrent with submission of the report. Unless DuPont notifies Bioamber otherwise, the report shall be submitted to: 

E. I. du Pont de Nemours and Company 
 [***] 
 A copy of the report shall be submitted concurrently to the office receiving
notices for DuPont in accordance with Section 8.1. 
 3.8. United States Dollars. 

3.8.1. Unless DuPont notifies Bioamber otherwise, all payments due to DuPont hereunder shall be in U.S. Dollars and shall be submitted by
wire transfer to: 
 [***] 
 3.8.2. In the event that royalties accrue in a currency other than U.S. Dollars, the royalties shall be converted into U.S. Dollars at the closing buying rate of the JPMorgan Chase Bank in effect on the
last business day of the accounting period for which payment is due; provided, however, DuPont may notify Bioamber, for future payments, of (a) another published currency conversion standard that shall apply, or (b) wire transfer
instructions for payment of royalties in the currency in which the royalties accrued. 

  
 10 

* Confidential treatment requested 

 3.9. Late Payments. If any payment due hereunder is not paid when due, the unpaid amount shall bear
interest at an annual rate of interest calculated at the Federal Reserve Prime Rate as reported by the Wall Street Journal on the date such payment is due, plus an additional [***], calculated on the number of days such payment is delinquent.
Such interest shall accrue on the balance of unpaid amounts from the date such amounts become due until payment in full. The penalty and interest available to DuPont pursuant to this Section shall in no way limit any other remedies available to
DuPont. 
 3.10. Record Retention. Bioamber shall keep, and require its sublicensees of the rights granted pursuant to Section 2.1.1
and/or 2.1.2 to keep, adequate records in sufficient detail to audit to completion Bioamber’s performance under, and compliance with, the terms of this Agreement and to verify the payments accrued, made, or to be made, and the accuracy of any
reports provided hereunder. Bioamber shall maintain such records for at least three (3) years following the date on which a royalty report is due. 
 3.11. Audit Rights. 
 3.11.1. DuPont shall have the right, upon fifteen
(15) days notice to Bioamber, to audit during regular business hours, those records deemed by the auditor to be reasonably necessary to audit to completion Bioamber’s performance under, and compliance with, this Agreement and to verify the
payments accrued, made, or to be made, and the accuracy of any reports provided hereunder. During such examination, the auditor’s right to examine includes without limitation those records required to maintained pursuant to Section 3.10,
as well as production and shipping logs and meeting notes and memoranda. 
 3.11.2. The auditor shall have the right, following
reasonable notice to Bioamber, to interview, during regular business hours, Bioamber’s employees or contractors who may have access to information deemed by the auditor to be reasonably necessary to audit to completion Bioamber’s
performance under, and compliance with, this Agreement and to verify the payments accrued, made, or to be made, and the accuracy of any reports provided hereunder. 
 3.11.3. The auditor shall be required to agree to terms of confidentiality consistent with this Agreement with respect to any confidential information it receives, provided that such agreement shall not
prohibit the reporting to DuPont of any finding under the Audit. Bioamber shall require any sublicensees of the rights granted in Sections 2.1.1 and 2.1.2 to maintain such records as are required under this Agreement. Bioamber shall require any such
sublicensees to allow DuPont to exercise the examination and interview rights granted hereunder with respect to any such sublicensee. . 
 3.11.4. Such examination and/or interviews shall not take place more often than once a year, nor cover any records or information that date prior to the date of the last such examination/interview.

 3.11.5. In the event the report demonstrates that Bioamber has underpaid any amount contemplated hereunder, Bioamber shall
promptly pay such amount together with interest calculated pursuant to Section 3.9. 
 3.11.6. [***]. 

  
 11 

* Confidential treatment requested 

	4.	CONFIDENTIAL INFORMATION 

 4.1.
Confidentiality and Non-Use. Confidential Information disclosed by a Disclosing Party to a Receiving Party shall be maintained in strict confidence by the Receiving Party, and not used for any purpose other than those authorized by this
Agreement, for [***] year period commencing from the Effective Date. Without limiting the foregoing, the Receiving Party shall not use Confidential Information to compete with or adversely affect the business or operations of the Disclosing
Party or its Affiliates or those doing business with them. The Receiving Party may disclose Confidential Information to the Receiving Party’s Representatives on a “need to know” basis, so long as such Representatives agree to be bound
by the obligations of confidentiality and non-use set forth in this Agreement or at least as strict as those set forth in this Agreement. The Receiving Party shall be responsible for any breach of the obligations of confidentiality and non-use set
forth in this Agreement by any of the Receiving Party’s Representatives. 
 4.2. Required Disclosure. If a Receiving Party is
required by law to disclose any Confidential Information, such Receiving Party shall (a) notify the Disclosing Party of such requirement sufficiently in advance of such required disclosure in order to permit the Disclosing Party to take steps
to prevent such disclosure, and (b) prior to any disclosure consult with and assist the Disclosing Party in obtaining a protective order or other appropriate measure. In any event, the Receiving Party will disclose only that portion of the
Confidential Information which is legally required and will use best efforts to assure that confidential treatment is accorded any Confidential Information so disclosed. 
 4.3. Equitable Relief. The Receiving Party acknowledges that (a) the Confidential Information disclosed to the Receiving Party by the Disclosing Party is the trade secret information of the
Disclosing Party, (b) any breach of the obligations of confidentiality and/or non-use set forth herein may cause irreparable harm to the Disclosing Party, (c) in the event of such breach, damages alone will not be an adequate remedy to the
Disclosing Party, and (d) in addition to all other remedies to which the Disclosing Party may be entitled hereunder or otherwise, the Disclosing Party may be entitled to injunctive relief, including specific performance, with respect to said
obligations in any court of competent jurisdiction. 
 4.4. Return of Confidential Information. Upon request by the Disclosing Party at
any time, the Receiving Party will promptly destroyed or return to the Disclosing Party (at the Disclosing Party’s sole option) the original and all copies of all the Disclosing Party’s Confidential Information and will, upon request,
certify in writing to the Disclosing Party as to the Receiving Party’s compliance with this paragraph, except that the Receiving Party may keep one (1) copy for archival purposes only. 

4.5. No Grant of Rights. Except as expressly set forth in this Agreement, the Receiving Party shall not be deemed to receive any right or license
under any Confidential Information disclosed by a Disclosing Party pursuant to this Agreement. 
 4.6. Press Release. Bioamber may not
issue any press release, advertisement, or any other communication concerning this Agreement, without the express written consent of DuPont. The Parties agree to release a press release of the form attached to this Agreement as Schedule C after the
exact wording of such a press release has been agreed to by the Parties. The exact wording of the press release shall be agreed to by the Parties within thirty (30) days of the Effective Date. The parties may issues future additional press
releases as the Parties may agree. 

  
 12 

* Confidential treatment requested 

	5.	WARRANTIES AND LIMITATIONS 

 5.1.
Representation. DUPONT REPRESENTS THAT IT HAS THE RIGHT TO GRANT THE RIGHTS GRANTED PURSUANT TO SECTIONS 2.1.1 AND 2.1.2 OF THIS AGREEMENT. 
 5.2. No Warranty of Success. DUPONT DOES NOT WARRANT OR GUARANTEE THAT ANY SUCCESSFUL COMMERCIAL RESULTS WILL BE OBTAINED BY BIOAMBER AS A RESULT OF EXERCISING THE RIGHTS GRANTED PURSUANT TO THIS
AGREEMENT. NEITHER DUPONT NOR ANY OF ITS AFFILIATES SHALL BE LIABLE TO BIOAMBER OR ANY OF BIOAMBER’S SUBLICENSEES BECAUSE OF ANY FAILURE IN BIOAMBER AND/OR ITS SUBLICENSEES OPERATIONS. 
 5.3. General Disclaimer of Warranty. THERE ARE NO OTHER WARRANTIES, EXPRESS OR IMPLIED, OTHER THAN THOSE EXPRESSLY EXTENDED IN THIS ARTICLE 5. 

5.4. No Warranty of Additional Obligation. DUPONT DOES NOT WARRANT OR GUARANTEE THAT BIOAMBER OR ANY OF ITS SUBLICENSEES OF THE RIGHTS GRANTED
PURSUANT TO SECTION 2.1.1 AND/OR 2.1.2 MAY PRACTICE THE RIGHTS GRANTED PURSUANT TO SECTIONS 2.1.1 AND/OR 2.1.2 ABSENT OBTAINING LICENSE RIGHTS FROM ANY THIRD PARTY, REGULATORY APPROVAL, AND/OR PERMITS. NEITHER DUPONT NOR ANY OF ITS AFFILIATES SHALL
BE LIABLE TO BIOAMBER OR ANY OF BIOAMBER’S SUBLICENSEES FOR COSTS INCURRED BY BIOAMBER OR ANY OF BIOAMBER’S SUBLICENSEES IN CONNECTION WITH OBTAINING ANY SUCH LICENSE RIGHTS, REGULATORY APPROVAL, AND/OR PERMIT. 

5.5. Confidential Information. Any Confidential Information provided hereunder is provided “AS IS,” without warranty of any kind,
including, without limitation, any warranty of non-infringement. 
 5.6. LIMITATION OF LIABILITY. IN THE EVENT BIOAMBER BRINGS AGAINST
DUPONT ANY CLAIMS, SUITS, OR CAUSES OF ACTION, SEEKING DAMAGES (INCLUDING, WITHOUT LIMITATION, ALL CLAIMS, AWARDS FOR DAMAGES, ATTORNEY FEES, COURT COSTS, INTEREST, PENALTIES, ETC.), IN ANY WAY RELATED TO THIS AGREEMENT OR ANY RIGHTS LICENSED TO
BIOAMBER UNDER THIS AGREEMENT OR ANY INFORMATION PROVIDED BY DUPONT TO BIOAMBER UNDER THIS AGREEMENT (INCLUDING WITHOUT LIMITATION A BREACH BY DUPONT OF ANY WARRANTY, REPRESENTATION OR OBLIGATION UNDER THIS AGREEMENT), BIOAMBER AGREES THAT THE TOTAL
COMBINED LIABILITY (INCLUDING, WITHOUT LIMITATION, LIABILITY FOR ALL CLAIMS, AWARDS FOR DAMAGES, ATTORNEY FEES, COURT COSTS, INTEREST, PENALTIES, ETC.) OF ALL DUPONT INDEMNITEES TO BIOAMBER RESULTING FROM ALL SUCH CLAIMS, SUITS, OR CAUSES OF ACTION
SHALL BE NO GREATER THAN FOUR HUNDRED THOUSAND DOLLARS ($400,000.00). 
 5.7. SPECIAL DAMAGES. NEITHER PARTY SHALL BE RESPONSIBLE TO THE
OTHER FOR SPECIAL, INCIDENTAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES THAT MAY BE INCURRED PURSUANT TO THIS AGREEMENT OR PERFORMANCE HEREUNDER. 

  
 13 

* Confidential treatment requested 

 5.8. HEALTH AND SAFETY. DUPONT DOES NOT WARRANT OR GUARANTEE THAT THE EXERCISE OF THE RIGHTS GRANTED
PURSUANT TO THIS AGREEMENT AND THE USE OF ANY PRODUCTS MADE PURSUANT TO THE PRACTICE OF SUCH RIGHTS WILL NOT RESULT IN SAFETY OR HEALTH HAZARDS TO WORKERS, THE ENVIRONMENT, OR TO PURCHASERS OF SUCH PRODUCTS. 

5.9. INDEMNIFICATION BY BIOAMBER. BIOAMBER HAS SOLE DISCRETION AND RESPONSIBILITY FOR ITS DESIGN, MAKING, MANUFACTURE, AND SALE OF PRODUCTS
PURSUANT TO THIS AGREEMENT. ACCORDINGLY, TO THE EXTENT PERMITTED BY THE LAW OF THE STATE OF DELAWARE, UNITED STATES OF AMERICA, BIOAMBER SHALL INDEMNIFY, DEFEND, AND HOLD THE DUPONT INDEMNITEES HARMLESS FROM AND AGAINST ANY AND ALL CLAIMS, SUITS,
OBLIGATIONS, CAUSES OF ACTION, LIABILITY, COSTS AND DAMAGES (INCLUDING, WITHOUT LIMITATION, ALL CLAIMS, AWARDS FOR DAMAGES, ATTORNEY FEES, COURT COSTS, INTEREST, PENALTIES, ETC), INJURIES TO PERSONS (INCLUDING DEATH) OR PROPERTY (INCLUDING, WITHOUT
LIMITATION, LOSS OF USE), PRODUCT LIABILITY CLAIMS, CLAIMS FOR PATENT INFRINGEMENT, CLAIMS BY THE OWNER OF THE SUBLICENSED PATENTS THAT PRACTICING HYDROGENATION AS PERFORMED BY BIOMABER VIOLATES THE TERMS OF ANY AGREEMENT [***] HAS WITH
DUPONT (EXCEPTING [***]), AND CLAIMS FOR DAMAGE TO THE ENVIRONMENT (COLLECTIVELY, “LIABILITIES”), WHATEVER THE CAUSE MAY BE, BASED UPON, ARISING OUT OF, OR RELATED TO THE ACTS OR OMISSIONS OF BIOAMBER AND ITS AFFILIATES AND/OR ANY
OF THEIR EMPLOYEES, OFFICERS, EMPLOYEES, AND CONSULTANTS,SUBLICENSEES OR OTHER PERSONS ACTING ON THEIR BEHALF OR UNDER THEIR CONTROL, IN CONNECTION WITH BIOAMBER’S AND/OR ANY BIOAMBER SUBLICENSEES’ EXECUTION, DELIVERY AND PERFORMANCE OF,
OR FAILURE TO PERFORM, THIS AGREEMENT, INCLUDING, WITHOUT LIMITATION, LIABILITIES ARISING OUT OF THE NEGLIGENCE OR WILLFUL MISCONDUCT OF ANY OF THE DUPONT INDEMNITEES, EXCEPT TO THE EXTENT THAT SUCH LIABILITIES ARE ESTABLISHED IN A COURT OF LAW TO
HAVE BEEN CAUSED SOLELY AND DIRECTLY BY THE NEGLIGENCE OR WILLFUL MISCONDUCT ON THE PART OF ANY OF THE DUPONT INDEMNITEES. 
 5.10.
Insurance. 
 5.10.1. Bioamber, at its expense, shall carry and maintain in force at all times relevant hereto the
following insurance, on policy forms and with insurance companies authorized to do business in the jurisdiction(s) where work is to be performed and acceptable to DuPont , at the indicated minimum coverage limits. Such insurance coverage shall be of
an “occurrence-based” basis, or Bioamber shall secure and maintain “tail insurance” coverage for acts occurring during the Term. DuPont shall be named as a loss payee and co-insured thereon (except for the policy for
Worker’s Compensation). Bioamber shall provide proof of such insurance to DuPont upon request. In the event DuPont has requested proof of such coverage and Bioamber has not provided such proof to DuPont within thirty (30) days of such
request, DuPont may obtain such coverage for Bioamber, at Bioamber’s expense, if the same is not obtained and proof thereof given to DuPont. 

  
 14 

* Confidential treatment requested 

 a. Workers’ Compensation - Statutory; Employer’s Liability - [***] per
accident/per employee; and such other insurance as may be required by Statutory law. This policy shall include a waiver of subrogation to DuPont. The obligation set forth in this Section is shall only apply if Bioamber builds and/or operates plants
producing Hydrogenation Products. 
 b. Commercial General Liability (Occurrence Form), including Contractual Liability and
liability for Products and Completed Operations, in a combined limit for Bodily Injury and Property Damage - [***] per occurrence. This policy shall name DuPont as additional insured. 

c. Other insurance appropriate for Bioamber’s business or as required by law. 

5.10.2. Bioamber shall maintain in force the insurance required by Sections 5.10.1 through 5.10.1.c, inclusive, and shall seasonably renew
all required coverage during the Term. 
 5.10.3. Upon the request of DuPont, Bioamber shall provide DuPont with certificates of
insurance evidencing the coverage. Such certificates shall be on a standard insurance industry form and underwritten by a carrier with an AM Best rating of A- or above. Such certificates shall provide that the insurer will give DuPont at least
thirty (30) days advance notice of any changes in, or cancellation or non-renewal of, coverage and note any exclusions. 

5.10.4. Bioamber shall require that any sublicensee carry the same coverage in the same limits as set out above and other coverage as
Bioamber deems appropriate and shall provide proof of such coverage. 
 5.10.5. Bioamber shall require that any subcontractor it
employs carry the same coverage in the same limits as set out above and other coverage as Bioamber deems appropriate and shall provide proof of such coverage. 
 5.10.6. Neither failure of Bioamber to comply with any or all of the insurance sections of the Agreement, nor the failure to secure endorsements on policies as may be necessary to carry out the terms and
sections of the Agreement, shall be construed to limit or relieve Bioamber from any of its obligations under the Agreement. 
  

	6.	TERM AND TERMINATION 

 6.1. Term.
This Agreement shall be in effect for the Term, unless earlier terminated in accordance with this Agreement. 
 6.2. Termination Without
Cause. During the Development Period, Bioamber may terminate this Agreement at any time, and for any reason whatsoever, by providing DuPont with thirty (30) days advance written notice of termination. Such termination shall be effective
thirty (30) days after DuPont’s receipt of the notice. 
 6.3. Termination for Cause. 

6.3.1. If Bioamber breaches, or defaults in the performance of, or fails to be in compliance with, any material warranty, representation,
agreement or covenant of this Agreement, other than a breach of its obligation to make any payment due under Article 

  
 15 

* Confidential treatment requested 

 
3, and such default or noncompliance shall not have been substantially remedied, or steps initiated to substantially remedy the same to DuPont’s reasonable satisfaction, within sixty
(60) days after receipt by Bioamber of a written notice thereof and demand to cure such default from DuPont, DuPont may terminate this Agreement. DuPont shall so terminate by providing a written notice of termination, and such termination shall
be effective as of the date of Bioamber’s receipt of the notice of termination. 
 6.3.2. If Bioamber breaches, or defaults
in the payment of any payment due under Article 3, and such default or noncompliance shall not have been substantially remedied, or steps initiated to substantially remedy the same to DuPont’s reasonable satisfaction, within thirty
(30) days after receipt by Bioamber of a written notice thereof and demand to cure such default from DuPont, DuPont may terminate this Agreement. DuPont shall so terminate by providing a written notice of termination, and such termination shall
be effective as of the date of Bioamber’s receipt of the notice of termination. 
 6.3.3. If DuPont breaches, or defaults in
the performance of, or fails to be in compliance with, any material warranty, representation, agreement or covenant of this Agreement, and such default or noncompliance shall not have been substantially remedied, or steps initiated to substantially
remedy the same to Bioamber’s reasonable satisfaction, within sixty (60) days after receipt by DuPont of a written notice thereof and demand to cure such default from Bioamber, Bioamber may terminate this Agreement. Bioamber shall so
terminate by providing a written notice of termination, and such termination shall be effective as of the date of DuPont’s receipt of the notice of termination. 
 6.4. Bankruptcy. Should Bioamber (1) become insolvent or unable to pay its debts as they mature, or (2) make an assignment for the benefit of creditors, or (3) permit or procure the
appointment of a receiver for its assets, or (4) become the subject of any bankruptcy, insolvency or similar proceeding, then DuPont may at any time thereafter terminate this Agreement. DuPont shall so terminate by providing a written notice of
termination, and such termination shall be effective as of the date of Bioamber’s receipt of the notice of termination. 
 6.5.
Termination for Patent Challenge. 
 6.5.1. In the event that Bioamber brings any Patent Challenge (except as required
under a court order or subpoena) then DuPont may immediately terminate this Agreement. DuPont shall so terminate by providing a written notice of termination, and such termination shall be effective as of the date of Bioamber’s receipt of the
notice of termination. 
 6.5.2. In the event that any such Patent Challenge brought by Bioamber is unsuccessful, Bioamber shall
reimburse DuPont for all reasonable legal fees and expenses incurred in its defense of the Patent Challenge. 
 6.6. Effect of
Termination. 
 6.6.1. On the date this Agreement is terminated for any reason prior to the end of the Term (the “Early
Termination Date”), Bioamber shall immediately cease performing Hydrogenation using the Sublicensed Patents and the Licensed Intellectual Property until the later of (a) the termination/expiration of the last to terminate/expire of the
Sublicensed Patents or (b) the end of the Exclusion Period. 

  
 16 

* Confidential treatment requested 

 6.6.2. Early termination of this Agreement shall not affect the rights and obligations of
either Party incurred prior to termination. For example, obligations to make payments then due, and to maintain Confidential Information in confidence, shall survive termination. Upon termination, each Party shall return Confidential Information of
the other Party, or destroy it, as the Disclosing Party shall instruct, and cease any use of Confidential Information of the other Party. 
 6.6.3. If this Agreement is terminated prior to the end of the Term other than pursuant to Section 6.3.3, Bioamber hereby grants to DuPont, (a) a non-exclusive, worldwide, royalty-free license
to use the Improvements, (b) a non-exclusive, worldwide, royalty-free license to any other know-how or developments made by or on behalf of Bioamber pursuant to Section 2.12 through 2.12.7, inclusive, related to the Sublicensed Patents
and/or the Licensed Intellectual Property, and (c) a non-exclusive, worldwide, royalty-free license to any license rights obtained by or on behalf of Bioamber that are necessary or desirable to allow DuPont to grant licenses pursuant to
Section 2.2.2. 
 6.6.4. If this Agreement is terminated prior to the end of the Exclusion Period other than pursuant to
Section 6.3.3, DuPont’s obligations set forth in Sections 2.7 through 2.7.1.b, inclusive, shall terminate concurrently with the termination of this Agreement. 
 6.7. Termination Not Sole Remedy. Unless otherwise specified, termination is not the sole remedy under this Agreement and, whether or not termination is effected, all other remedies will remain
available except as expressly agreed to herein. 
 6.8. Provision of Documents and Information. In addition to Bioamber’s obligation
to return or destroy DuPont Confidential Information pursuant to Section 4.4, within ten (10) days of the termination or expiration of this Agreement, Bioamber shall (a) destroy or return to DuPont (at DuPont’s sole option) the
original and all copies of all DuPont’s Confidential Information (except that Bioamber may keep one (1) copy for archival purposes only); (b) destroy or return to DuPont (at DuPont’s sole option) all documents containing
derivative information based on such Confidential Information; and provide DuPont with copies of tangible embodiments of any other know-how or developments made by or on behalf of Bioamber pursuant to Section 2.12 through 2.12.7, inclusive,
related to the Sublicensed Patents and/or the Licensed Intellectual Property. Bioamber will, upon DuPont’s request, certify in writing to DuPont as to Bioamber’s compliance with this Section 

6.9. Survival. The provisions of Sections 2.6.1 through 2.6.4, inclusive, 3.9 through 3.11.6, inclusive, 6.7, and 6.9 and Articles 1, 4, 5, and 8
shall survive the expiration or termination of this Agreement. The obligation to pay amounts accrued under Article 3 prior to termination shall survive the expiration or termination of this Agreement. For the sake of clarity, the Parties each agree
that the obligation to pay royalties and minimum royalties set forth in Sections 3.2 through 3.3.2, inclusive, shall not survive early termination of this Agreement. 
  

	7.	DISPUTE RESOLUTION. 

 7.1. Senior
Executive Panel. If any dispute or claim arising under the Agreement cannot be readily resolved by the Parties, the Parties shall refer the matter to a panel consisting of one (1) senior executive from each party for review and resolution.
The senior executive shall not have been directly involved in the claim or dispute. A copy of the Agreement terms, relevant facts, areas of disagreement, and concise summary of the basis for each side’s contentions will be

  
 17 

* Confidential treatment requested 

 
provided to both executives who shall review the same, confer, and attempt to reach a mutual resolution of the issue. The senior executives shall attempt to meet in person or by phone and resolve
the dispute within thirty business (30) days of their appointment. 
  

	7.2.	Mediation. 

 7.2.1. If the
dispute cannot be resolved by the senior executive panel within ten (10) days of the date of the senior executive’s conference, then the Parties shall submit the matter to mediation within thirty (30) days thereafter in accordance
with the rules of the American Arbitration Association, as modified herein, and each Party shall bear equally the costs of the mediation. Unless otherwise agreed by the Parties, the mediation will take place in Wilmington, Delaware. 

7.2.2. The Parties will jointly appoint a mutually acceptable mediator, seeking assistance in such regard from the American Arbitration
Association if they are unable to agree upon such appointment within twenty (20) days from the conclusion of the negotiation period. 
 7.2.3. The Parties agree to participate in good faith in the mediation and negotiations related thereto for a period of thirty (30) days or such longer period as they may mutually agree following the
initial mediation session. 
 7.2.4. The mediator, prior to any proceedings hereunder, will sign an agreement whereby any such
mediator(s) agrees to keep the existence and substance of any proceedings hereunder in confidence. 
 7.3. Legal /Equitable Remedy. In
the event the mediation fails to yield mutually satisfactorily results, nothing herein, however, shall preclude either Party from seeking remedy of a dispute in a court of law or equity in accordance with Section 8.2. 

THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK 

  
 18 

* Confidential treatment requested 

	8.	MISCELLANEOUS 

 8.1. Notices. Any
notice or other communication required or permitted to be given by either Party under this Agreement shall be in writing and shall be effective when delivered, if delivered by hand or by electronic facsimile or by courier or five (5) days after
mailing if mailed by registered or certified mail, postage prepaid and return receipt requested. All such notices shall be addressed to each Party at the following addresses or such other address an may be designated by notice pursuant to this
Section: 
  

			
	 If to DuPont:
 E. I. du Pont de Nemours and Company
 [***]
	 	 If to Bioamber:
 Bioamber s.a.s.
 1250 Rene-Levesque West, Suite 4110

Montreal, Quebec, Canada
 H3B 4W8
 Attn: Mr. Jean-François Huc, Director General

Phone : [***]
 E-Mail : [***]
 Facsimile : [***]

		 	 With a copy to :
 Boivin Desbiens Senecal, g.p.
 [***]

 8.2. Choice of Law. The validity, interpretation and performance of this Agreement and any disputes arising
thereunder shall be governed and construed in accordance with the laws of the State of Delaware, without regard to the conflict of law principles thereof. This Agreement shall not be governed by the U.N. Convention on Contracts for the International
Sale of Goods. Any legal action arising from a dispute or question regarding the terms and conditions, or performance of this Agreement may be instituted only in the appropriate court for the State of Delaware or the United States District Court for
the District of Delaware. Matters between the Parties pertaining to the validity or enforceability of United States Sublicensed Patents shall be instituted only in the United States District Court for the District of Delaware. Matters pertaining to
the validity or enforceability of Sublicensed Patents, other than United States Sublicensed Patents, shall be interpreted and enforced in accordance with the laws of the territory in which such Sublicensed Patents exist. The Parties consent to the
personal jurisdiction and waive any objection to the venue of these courts. The Parties further consent that any service of process may be served by overnight courier or express mail at the respective addresses stated in Section 8.1.

 8.3. Assignment. This Agreement may be assigned or transferred by a Party to such entity that is the successor to substantially all of
those business assets of the Party to which this Agreement applies, provided that the Party gives written notice thereof to the other Party within a reasonable time and such successor agrees in writing to abide by the terms and conditions hereof.
Either Party may delegate performance hereunder, in whole or in part, to an Affiliate(s), but shall remain responsible for performance of its obligations hereunder. Notwithstanding the above, Bioamber shall not, and shall have no right to, assign
this Agreement (a) any entity that DuPont would be barred from entering into the Agreement with under an law or regulation or (b) any entity in a country listed in Country Group E of the CFR Section 15 Supplement 1 to Part 740.

  
 19 

* Confidential treatment requested 

 8.4. Compliance with Laws. The Parties shall abide by the laws and regulations of the United States,
including, without limitation, Export Control and related regulations that pertain to the export of technology. 
 8.5. Independent
Contractors. Each Party shall remain an independent contractor. Nothing herein shall be construed as creating an agency or joint venture relationship between the Parties 
 8.6. Entire Agreement; Merger. This Agreement constitutes the entire agreement between the Parties concerning the subject matter contained herein. Any prior agreement between the Parties is
subsumed by this Agreement. Any modifications shall be in writing, duly signed by both Parties. Any prior agreement, arrangement or undertaking, whether oral or in writing is hereby superseded. 

8.7. Force Majeure. No Party shall be liable for any failure or delay in performance under this Agreement to the extent that, and for the period
that, such failure or delay arises from Force Majeure and the affected Party has informed the other Party within five (5) business days in detail of the Force Majeure event. A Force Majeure consists of an event beyond the reasonable control of
the affected Party and includes, without limitation, fire, explosion, earthquake, storm, flood, strike, labor difficulties, war, insurrection, riot, act of God or the public enemy, or any law, act, order, export or import control regulations,
proclamation, decree, regulation, ordinance, or instructions of local, state, federal or foreign governmental or other public authorities, or judgment or decree of a court of competent jurisdiction (but excluding a court injunction against a
Party’s performance) and not otherwise arising out of breach by such Party of this Agreement. In the event of the occurrence of such an event, the Party so affected shall give prompt written notice to the other Party, stating the period of time
the occurrence is expected to continue and shall use best efforts to end the failure or delay and ensure that the effects of such Force Majeure are minimized. 
 8.8. Beneficiaries. No person, other than Bioamber or DuPont and their permitted assignees hereunder, shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation
of this Agreement. 
 8.9. Advice of Counsel. DuPont and Bioamber have each consulted counsel of their choice regarding this Agreement,
and each acknowledges and agrees that this Agreement shall not be deemed to have been drafted by one Party or another and will be construed accordingly. 
 8.10. No Trademark Rights. Except as provided herein, no right, express or implied, is granted by this Agreement to use in any manner the name “DuPont,” or any other trade name or
trademark of DuPont or its Affiliates or “Bioamber,” or any other trade name or trademark of Bioamber or its Affiliates in connection with performance of this Agreement. 
 8.11. Waiver. No waiver of any rights or consent under this Agreement shall be deemed effective unless contained in writing signed by the Party charged with such waiver or consent, and no waiver of
any breach or failure to perform shall be deemed a waiver of any future breach or failure to perform or any other right arising under this Agreement. 
 8.12. Headings. The section headings contained in this Agreement are included for convenience only and form no part of the agreement between the Parties 

  
 20 

* Confidential treatment requested 

 IN WITNESS WHEREOF, the Parties have executed this Agreement. 

 

					
	Bioamber S.A.S.	 		 	E. I. du Pont de Nemours and Company
			
	 /s/ Jean-François Huc
	 		 	 /s/ [***]

	Signature	 		 	Signature
			
	 Jean-François Huc
	 		 	 [***]

	Printed Name	 		 	Printed Name
			
	 Director General
	 		 	 [***]

	Title	 		 	Title

  
 21 

* Confidential treatment requested 

 SCHEDULE A 
 [***] 

  
 22 

* Confidential treatment requested 

 SCHEDULE B 
 TECHNICAL REPORTS 
 [***] 

  
 23 

* Confidential treatment requested 

 SCHEDULE C 
 Form of Press Release 
 Bioamber and DuPont Collaborate on Derivatives of
Biobased Succinic Acid 
 Princeton, NJ – July 1, 2010 – Bioamber, a joint venture between DNP Green Technology and ARD, and
E. I. du Pont de Nemours and Company (DuPont), have announced a strategic collaboration in the field of biobased derivatives of succinic acid. Under the terms of the agreement, Bioamber has licensed certain DuPont technology and DuPont has a right
of first refusal to secure off-take from future commercial plants. 
 Bioamber, which recently commissioned the world’s first biobased
succinic acid plant, is actively developing technologies to transform biobased succinic acid into value added derivative products. “DuPont’s technology will accelerate our development program and shorten our time to market” stated
Jean-Francois Huc, President of DNP Green. “Our collaboration with DuPont will help ensure that we are first to market, and it could reduce the commercial risk associated with building large plants” he added. 

About Bioamber 
 Bioamber is the joint
venture between DNP Green Technology and Agro-industrie Recherches et Développements (ARD) that is dedicated to succinic acid. Bioamber possesses the only biobased succinic acid technology that has been proven at a commercial scale. Bioamber
recently commissioned the world’s first and only biobased succinic acid plant in Pomacle, France. For more information, visit www.bio-amber.com 
 About DuPont 
 To be completed 

About DNP Green Technology 
 DNP Green
Technology is a private US company that produces renewable chemicals. Through numerous scientific and business partnerships, DNP Green Technology has built an extensive IP portfolio and know-how covering the production, purification and uses of
biobased succinic acid and derivatives including modified PBS, a biodegradable polymer. DNP Green is actively developing other bio-based chemical platforms, leveraging industrial biotechnology and chemical synthesis to produce renewable chemicals
and bio-based materials. The company has offices in Princeton, N.J., Shanghai, China and Montreal, Canada. For more information, visit www.dnpgreen.com 
 About ARD 
 ARD (Agro-Industrie Recherches et Développements) is the R&D centre
of a large agro-industrial consortium based in Champagne-Ardenne, France. Member of the global-scale competitiveness cluster IAR (Industries and Agro-Resources), ARD adds value to and finds new outlets for agricultural crops. It develops innovative
and competitive bio-based molecules produced in bio-refineries. With its subsidiary SOLIANCE, specialized in the production and commercialization of cosmetics active ingredients, ARD has 25 years of experience in biomass fractionation, bio-based
chemistry, and industrial biotechnology. ARD and its affiliates employ over 130 people. For more information, please visit www.a-r-d.fr 
 For
More Information: 
 Mike Hartmann 
 VP
Corporate 
 DNP Green Technology 

E-mail: mike.hartmann@dnpgreen.com 
 Phone +1
(514) 844-8000 x120 

  
 24 

* Confidential treatment requested 

 AMENDMENT TO THE LICENSE AGREEMENT ENTERED INTO BETWEEN E. I. DU PONT DE NEMOURS AND
COMPANY AND BIOAMBER S.A.S. AND ENTERED INTO FORCE AS OF JUNE 28, 2010 
  

This Amendment Agreement (the Amendment”) is made as of
February 18th, 2011 and is to be effective nunc
pro tunc, as of June 28, 2010, between E.I. du Pont de Nemours and Company (“DuPont”) and BioAmber S.A.S. (“BioAmber”). 
 WHEREAS DuPont and BioAmber entered into a License Agreement which entered into force on June 28, 2010 (the “Agreement”); 
 WHEREAS the parties desire to amend the Agreement as set forth herein; 
 NOW THEREFORE, DuPont and
BioAmber agree to amend the Agreement as follows: 
  

	1.	Sections 1.3 through 1.3.3, inclusive shall be replaced with the following: 

 1.3. “Confidential Information” means information disclosed by BioAmber hereunder when such is identified as the confidential information of BioAmber. Tangible embodiments of information shall
be deemed as “identified as confidential information” if clearly labeled as “Confidential” or “Proprietary” or with some other legend or marking indicating the confidential nature of the information. Information that is
disclosed verbally or by other non-tangible disclosure to DuPont shall be deemed as “identified as confidential information” if it is set forth by BioAmber in a writing clearly labeled “Confidential” or “Proprietary” or
with some other legend or marking indicating the confidential nature of the information, and the writing is delivered to DuPont within fifteen (15) days of said verbal/non-written disclosure. Information disclosed verbally or by other
non-written disclosure to DuPont shall be treated as Confidential Information during the fifteen (15) day period following such disclosure. 
 1.3.1. Information shall not be considered Confidential Information to the extent that any such information was (a) as of the date of disclosure to DuPont, known to DuPont and such knowledge can be
substantiated by reasonable documentation; (b) as of the date of disclosure to DuPont, disclosed in published literature or generally available to the public; (c) after the date of disclosure to DuPont, disclosed in published literature or
generally available to the public, other than by a breach by DuPont of the obligations of confidentiality and non-use set forth in this Agreement; (d) developed by DuPont independently from, and without exposure to, the information provided by
BioAmber; or (e) obtained by DuPont from a third party without binder of secrecy, provided that such third party had no obligation of confidentiality to BioAmber or any of its Affiliates relating to the Confidential Information. 

1.3.2. Information disclosed hereunder shall not be deemed to be within the exceptions merely set forth in Section 1.3.1 merely
because such information is embraced by more general knowledge in the public domain or in DuPont’s possession. In addition, no combination of features shall be deemed to be within the foregoing exceptions merely because individual features are
in the public domain or in DuPont’s possession, but only if the combination itself and its principles of operation are in the public domain or in DuPont’s possession. 
 1.3.3. For the purposes of Sections 1.3 through 1.3.3, inclusive, “information” includes, without limitation, all information relating to existing and potential inventions (whether or not
reduced to practice), discoveries, know-how, technologies, reports, data, results, observations, computer programs, patent applications, hypotheses, research directions, 

  
 1 

* Confidential treatment requested 

 
developments, improvements, drawings, designs, specifications, methodologies, algorithms, formulas, protocols, strategic plans, business plans, business opportunities, draft and/or final
regulatory filings, customers, potential customers, suppliers, markets, contracts, prices, products, personnel, strategies, policies, systems, procedures, information, processes, research, applications, methods of manufacture and any other
information relating to BioAmber or any of its Affiliates. 
  

	2.	Section 1.8 shall be deleted in its entirety. 

  

	3.	Section 1.19 shall be deleted in its entirety. 

  

	4.	Section 1.20 shall be replaced with the following: 

 1.20. “Representatives” means the directors, officers, employees, agents, contractors, and/or Affiliates of DuPont to whom DuPont needs to disclose Confidential Information in connection with
the Parties’ performance under this Agreement. 
  

	5.	Section 6.6.2 shall be replaced with the following 

 6.6.2. Early termination of this Agreement shall not affect the rights and obligations of either Party incurred prior to termination. For example, obligations to make payments then due, and to maintain
Confidential Information in confidence, shall survive termination. Upon termination, DuPont shall return Confidential Information to BioAmber, or destroy it, as BioAmber shall instruct, and cease any use of BioAmber Confidential Information.

  

	6.	Article 4, Inclusive, shall be replaced with the following. 

  

	 	4.	CONFIDENTIAL INFORMATION 

4.1. Confidentiality and Non-Use. Confidential Information disclosed by BioAmber to DuPont shall be maintained in strict confidence
by DuPont and not used by DuPont for any purpose other than those authorized by this Agreement, for a fifteen (15) year period commencing from the Effective Date. Without limiting the foregoing, DuPont shall not use Confidential Information to
compete with or adversely affect the business or operations of BioAmber or its Affiliates or those doing business with them. DuPont may disclose Confidential Information to DuPont’s Representatives on a “need to know” basis, so long
as such Representatives agree to be bound by the obligations of confidentiality and non-use set forth in this Agreement or at least as strict as those set forth in this Agreement. DuPont shall be responsible for any breach of the obligations of
confidentiality and non-use set forth in this Agreement by any of DuPont’s Representatives. 
 4.2. Required
Disclosure. If DuPont is required by law to disclose any Confidential Information, DuPont shall (a) notify BioAmber of such requirement sufficiently in advance of such required disclosure in order to permit BioAmber to take steps to prevent
such disclosure, and (b) prior to any disclosure consult with and assist BioAmber in obtaining a protective order or other appropriate measure. In any event, DuPont will disclose only that portion of the Confidential Information which is
legally required and will use best efforts to assure that confidential treatment is accorded any Confidential Information so disclosed. 
 4.3. Equitable Relief. DuPont acknowledges that (a) the Confidential Information disclosed to DuPont by BioAmber is the trade secret information of BioAmber, (b) any breach of the
obligations of confidentiality and/or non-use set forth herein may cause irreparable harm to BioAmber, (c) in the event of such breach, damages alone will not be an adequate remedy to BioAmber, and (d) in addition to all other remedies to
which BioAmber may be entitled hereunder or otherwise, BioAmber may be entitled to injunctive relief, including specific performance, with respect to said obligations in any court of competent jurisdiction. 

  
 2 

* Confidential treatment requested 

 4.4. Return of Confidential Information. Upon request by BioAmber at any time, DuPont
will promptly destroyed or return to BioAmber (at BioAmber’s sole option) the original and all copies of all BioAmber’s Confidential Information and will, upon request, certify in writing to BioAmber as to DuPont’s compliance with
this paragraph, except that DuPont may keep one (1) copy for archival purposes only. 
 4.5. No Grant of Rights.
Except as expressly set forth in this Agreement, DuPont shall not be deemed to receive any right or license under any Confidential Information disclosed by BioAmber pursuant to this Agreement. 

4.6. Press Release. Bioamber may not issue any press release, advertisement, or any other communication concerning this Agreement,
without the express written consent of DuPont. The Parties agree to release a press release of the form attached to this Agreement as Schedule C after the exact wording of such a press release has been agreed to by the Parties. The exact wording of
the press release shall be agreed to by the Parties within thirty (30) days of the Effective Date. The parties may issues future additional press releases as the Parties may agree. 

 

	7.	The Schedules A and B of the Agreement are deleted and replaced by the Schedules A and B attached hereto, which form an integral part hereof. 

 

	8.	The provisions of the Agreement not modified herein shall continue to be in force as stated in the Agreement. 

IN WITNESS WHEREOF, the parties hereto have signed this agreement as of the date first written above. 

 

									
	E. I. du Pont de Nemours and Company	 		 	BioAmber S.A.S.
					
	By:	 	 /s/ [***]
	 		 	By:	 	 /s/ Jean-François Huc

	Signature	 		 	Jean-François Huc
		 		 	President
	 [***]
	 		 		 	
	Name and Title	 		 		 	

  
 3 

* Confidential treatment requested 

 SCHEDULE A 
 [***] 

  
 4 

* Confidential treatment requested 

 SCHEDULE B 
 TECHNICAL REPORTS 
 [***] 

  
 5 

* Confidential treatment requestedToll Manufacturing Agreement

 Exhibit 10.36 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested

 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 203.406 
 TOLL MANUFACTURING AGREEMENT 

THIS TOLL MANUFACTURING AGREEMENT (the “Agreement”), signed on September 30th, 2010, is made and entered into by and among Agro Industrie
Recherches et Développements, S.A., a French entity (“ARD”), Bioamber, S.A.S., a French entity (“Bioamber”) and DNP Green Technology, Inc., a Delaware corporation (“DNP Green”). 

PRELIMINARY STATEMENTS 
 WHEREAS DNP Green, ARD and Bioamber have signed a Transitional Work Plan Agreement as of September 30th, 2010 (the “Transitional Work Plan Agreement”) providing for the possible entry into force of a Toll
Manufacturing Agreement; 
 WHEREAS, Bioamber agrees to grant, for the duration of this Agreement, to ARD a non-exclusive,
worldwide, royalty free license to any intellectual property rights (“IP”) (i.e. any required licensed patents and licensed know-how granted by DNP Green to Bioamber as defined in the License Agreement between DNP Green and Bioamber dated
25 September 2008, with the exclusion of the Derivative Products) required solely for ARD to perform its obligations as defined in this Agreement. ARD shall have the right to sublicense any of the aforementioned rights to third parties.
ARD’s permitted use of the rights granted pursuant to the aforementioned license or sub-licenses shall be solely limited to the performance by ARD of its obligations provided in this Agreement. 

WHEREAS DNP Green accepts to warrant the performance by Bioamber of all its obligations mentioned in this Agreement. 

WHEREAS ARD and Bioamber now wish to agree on the terms and conditions of such Toll Manufacturing Agreement; 

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged by each party, and intending to be legally bound hereby, the parties agree as follows: 
 STATEMENT OF AGREEMENT 
  

	1.	TOLL MANUFACTURING  

  

	 	1.1	 Bioamber hereby agrees to retain the services of ARD for the production of succinic acid (the “Product”), at ARD’s succinic acid
demonstration plant, possessing an initial annual production capacity of [***] and located at Pomacle, 

  
 1 

 * Confidential treatment requested 

	 	
France, adjacent to the Chamtor wheat mill (“Demonstration Plant”), for a quantity of Product limited to the production capacity of such demonstration plant and according to the
terms and conditions provided in this Agreement, it being understood that the Demonstration Plant capacity is expected to increase over time as a result of improved fermentation titers or improved recovery yields. 

ARD shall provide such services to Bioamber on an exclusive basis, and ARD agrees that, for the term of this Agreement, no other
activity will be conducted at the Demonstration Plant without the prior written approval of Bioamber. In the event that the Demonstration Plant is not operating at full capacity, ARD will have the ability to propose to a third-party manufacturing
services in the Demonstration Plant to produce non-succinic acid related products, in order to reduce labor costs for Bioamber. Such third party manufacturing services shall be at Bioamber’s sole discretion and Bioamber shall be under no
obligation to accept the production of non-succinic acid related products. For the avoidance of doubt, in the event that ARD does not find a third- party duly approved by Bioamber accepting to enter into a manufacturing contract in the Demonstration
Plant to produce non-succinic acid related products, Bioamber shall have to pay to ARD all the labor costs borne by ARD as provided in this Agreement resulting directly from the Demonstration Plant not operating at full capacity. DNP Green shall
also have the right to propose a third party for manufacturing services to reduce labor costs, subject to the approval of ARD; should ARD not give its approval, Bioamber shall have to pay ARD according to the provisions hereinabove. 

 

	2.	SPECIFICATIONS 

  

	 	2.1	ARD agrees that it shall manufacture the Product in accordance with the specification sheets listed in the Transitional Work Plan Agreement and attached hereto as
Schedule W (the “Product Specifications”). The parties recognize that the Product Specifications are subject to change over the term of this Agreement. After each production batch, and at any other time upon Bioamber’s request,
ARD shall deliver to Bioamber samples of the Product manufactured by ARD and the results of its analytical tests. 

  

	 	2.2	In the event of a material change of the Product Specifications that would trigger additional costs and/or a material change to the production process, and/or material
change of schedule for ARD, Bioamber shall assume such additional costs through the adjustment of the Target Usage Factors and the consequent Price paid by Bioamber for a metric ton of succinic acid produced. 

 

	3.	LABELLING AND PACKING 

  

	 	3.1.	ARD shall package and label the Product so as to conform with the specifications relating to labelling and packing (the “Packaging Specifications”)
provided from time to time by Bioamber. ARD shall be solely responsible for insuring that the Product is labelled and packed in conformity with the Packaging Specifications. 

  
 2 

 * Confidential treatment requested 

	 	3.2.	ARD shall supply at Bioamber’s cost the material required to effect the labelling and packing of the Product (the “Packing Materials”). ARD will
be responsible for the quality of the Packing Materials. In the event of a change to the Packaging Specifications that would trigger additional costs and/or change of process or material change of schedule for ARD, Bioamber shall pay any additional
costs related therewith. 

  

	4.	MODIFICATIONS TO THE SPECIFICATIONS 

  

	 	4.1	ARD will not make any changes in the specifications covering the manufacturing or processing of the Product or the production process without the express written
consent of Bioamber. Bioamber may modify the Product Specifications, the Packaging Specifications or the Quality Standards (as defined in Section 5.2 below) by giving written notice of such change to ARD. Any change in the Product
Specifications or the Packaging Specifications that would have an adverse effect on the production costs or schedule of the Product or on the process will be subject to good faith negotiations by the parties as to modifications in the Price and/or
delivery schedule of the Product. ARD shall not be required to implement any changes in the Product Specifications or in the Packaging Specifications to the extent that these changes are impracticable as a result of a cause or causes outside the
reasonable control of ARD, including without limitation infeasible technological requirements or to the extent the approval of the changes would require ARD to violate any applicable laws, rules or regulations or would result in the breach of any
agreement, including without limitation, any confidentiality, non disclosure, or license agreement. 

  

	5.	CONTROL AND QUALITY 

  

	 	5.1.	 A Steering Committee will be put in place following the entry into force of this Agreement, consisting of one representative designated by Bioamber
from time to time and one representative designated by ARD from time to time. Such committee (i) will oversee the application of this Agreement and any process development or optimization work and (ii) shall remain in force until the
termination of this Agreement. In the event of any disagreement, the parties undertake to cooperate with diligence and good faith in order to find an amicable solution to any dispute that may arise between them, it being understood that Bioamber, as
exclusive beneficiary of the Demonstration Plant and the party liable for the operational cost of the Demonstration Plant during the term of this Agreement, shall make the final decision. If an amicable solution is not found and agreed to between
the members of the Steering Committee with respect to any disagreement within a period of two (2) weeks from its occurrence, Bioamber shall have the sole authority to make a final decision regarding the concerned disagreement. In the event that
Bioamber imposes a decision that ARD does not agree with, and ARD notifies Bioamber of its objection in writing, indicating the 

  
 3 

 * Confidential treatment requested 

	 	
reasons for its objection, Bioamber shall be responsible for any cost related to lost batches or partially lost batches that are the direct result of the decision imposed by Bioamber, if ARD has
complied with all standard operating procedures and fulfilled its obligations under this Agreement, subject to all applicable laws. 

  

	 	5.2.	ARD is to manufacture the Product in accordance with the Product Specifications and the prescribed quality norms and standards of good workmanship, as determined by
Bioamber in collaboration with ARD (the “Quality Standards”) as attached in Schedule X. The Quality Standards may be amended, as provided for in Section 4.1. In case of change of the Quality Standards that would trigger
important additional costs and/or important changes to the process or an important change of schedule for ARD, the Parties agree to find an amicable solution in their mutual interest. 

 

	 	5.3.	ARD and Bioamber shall conform to all applicable laws and regulations relating to manufacturing, processing, storing and shipping of Product. 

 

	6.	EXCLUSIVE RIGHTS 

  

	 	6.1.	Except as may be otherwise provided in this Agreement, ARD covenants to manufacture and furnish the Product exclusively to Bioamber or parties designated by Bioamber
subject to QC Release by Bioamber. Furthermore, ARD covenants that it shall in no way apply any aspect of the IP to which ARD may have access in connection with this Agreement in the manufacture of the Product for third parties unless expressly
authorised by Bioamber. 

  

	7.	PRICE 

  

	 	7.1	The parties agree that, in consideration of the manufacture by ARD of the Product in accordance with the terms of this Agreement, Bioamber will pay to ARD, (i) 50%
of the capital investments or equipment leasing required for new unit operations related to improving product quality, and (ii) the following: 

  

	 	7.1.1	A price calculated in Euros per metric ton of Product produced by ARD according to the terms of this Agreement, duly approved by Bioamber in accordance with the terms
of Section 9 and being QC Release by Bioamber, which price shall be calculated as follows: the Target Usage Factors listed in Schedule Y attached hereto or in effect at that time, multiplied by the Ingredients’ unit cost then in effect
[***], which amount shall be adjusted periodically, in the following manner: 

  

	 	(i)	[***]; 

  

	 	(ii)	[***]; 

  

	 	7.1.2	A tolling fee of [***] of any amount paid by Bioamber to ARD as provided in subsection 7.1.1 above; 

  
 4 

 * Confidential treatment requested 

	 	7.1.3	One Hundred percent (100%) of the labor costs related to [***] Any new hiring of staff will be subject to the prior written consent of Bioamber, it being
understood that any increase in labor costs resulting from laws or applicable regulations, as well as a 3% annual increase in employees’ salaries, shall not be subject to Bioamber consent. Any changes to the labor costs listed in Schedule Z
will require the prior written consent of Bioamber which shall act reasonably taking into account the content of this paragraph. 

  

	8.	INVOICES, PAYMENT 

  

	 	8.1.	ARD shall submit original invoices to Bioamber in form, substance and format reasonably acceptable to Bioamber, on a monthly basis, within forty-five (45) days
following each month during which this Agreement will be in force. All invoices must reference Bioamber’s Purchase Order number, contain an itemization of the amount of Product provided in connection with the applicable invoice period and any
other information reasonably requested by Bioamber, including the invoices received by ARD related to any costs to be borne by Bioamber pursuant to the Agreement, and must otherwise comply with the provisions of this Agreement and such reasonable
requirements as may be prescribed by Bioamber from time to time. Invoices shall be addressed as directed by Bioamber. 

 Bioamber is to pay any undisputed invoice submitted by ARD concerning the Product within fifteen (15) days of receipt of such invoice. 

 

	9.	DELIVERY 

  

	 	9.1.	The Product ordered by Bioamber shall be delivered on behalf and under the sole liability, ownership and risk of Bioamber as from QC Release (as hereinafter defined) to
the place and as per the schedule of delivery indicated by Bioamber in the Purchase Order duly approved by ARD (as provided in Section 10 below). 

  

	 	    	The parties agree that ARD will organise and monitor, in the name and on behalf of Bioamber, the shipping of the Product from its premises to Bioamber’s clients
locations or to any other place mentioned by Bioamber in the Purchase Order. Any costs of delivery from ARD premises to Bioamber’s clients locations will be paid entirely by Bioamber and any liability with respect to this delivery shall be
fully borne by Bioamber. 

  

	 	9.2.	 The acceptance of the Product and the payment thereof (as provided in Section above), by Bioamber, shall at all times take place under reserve of
inspection and approval by Bioamber that shall be completed by Bioamber no later than ten (10) business days after having received the analytical data from the Demonstration Plant and the ARD analytical labs that is needed to prepare a
certificate of 

  
 5 

 * Confidential treatment requested 

	 	
analysis. Bioamber shall have the right to refuse all or part of the production at no cost to itself, in consideration of the fact that the Product does not conform with the Purchase Order.
Bioamber may issue reservation and make claims by email with confirmation of receipt sent to ARD within ten (10) business days after having received the analytical data from the Demonstration Plant and ARD analytical labs in the conditions set
forth in Section 11, it being understood that the Bioamber inspection is to be undertaken after the toll manufacturing of a batch by ARD is completed and the analytical data has been communicated to Bioamber. ARD shall be in position to remedy
the reservations and claims at any time within thirty (30) days as of the reception of the above mentioned reservations and claims. ARD shall be responsible for all costs reasonably incurred for unpacking, inspection, repacking and storing of
any Product refused by Bioamber by virtue of this Section 9.2 and ARD shall pay such costs upon presentation of documents as proof. For sake of clarity, should Bioamber avail itself of any of its rights provided in this Section 9.2, the
title of ownership and the risk of loss shall not be transferred to Bioamber and ARD shall thus be responsible for any costs or loss. 

 In the event of any disagreement between ARD and Bioamber stemming from the refusal by Bioamber to approve any Product in connection with Bioamber’s right of inspection and approval provided in this
subsection 9.2, ARD and Bioamber agree to jointly designate a qualified third party analytical lab who shall proceed with another analysis of the concerned Product and shall determine if such Product is in accordance or not with the Purchase Order.
Such jointly designated third party shall have the authority to make a final decision with respect to such disagreement. 
  

	 	9.3.	If a force majeure event, as defined hereafter, occurs between the receipt of the Purchase Order and the stated date for the delivery of the Product, and if this event
prevents delivery within the time period stated on the Purchase Order forms, ARD must inform Bioamber immediately by fax or e-mail with confirmation of receipt within 3 (three) business days at the latest as of the occurrence of the force majeure
event. 

 If ARD does not comply with the provisions stipulated in the preceding paragraph, it shall not be able
to rely on any event of force majeure. 
  

	 	9.4.	Neither party may be held liable towards the other for any breach of its obligations hereunder if the sole cause of such breach is a force majeure event.

 A force majeure event means an event beyond the control of the party which has not performed its obligation,
such as strikes, natural disaster, social unrest, war, unavailability of means of transport, embargo. 
 The performance of
obligations shall resume its normal course as soon as the force majeure event has ceased. 

  
 6 

 * Confidential treatment requested 

 If the force majeure event lasts longer than a period of three months, each party shall
have the option of automatically terminating this Agreement without damages due from either side. 
  

	10.	PURCHASE ORDER 

  

	 	10.1.	ARD shall manufacture the Product as provided in purchase orders received from Bioamber (“Purchase Orders”). In the event ARD is to proceed with the
shipment of any Product, it is agreed that any such shipment of Products shall be made by ARD on behalf and under the sole liability, ownership and risk of Bioamber as from QC Release, it being understood that any cost resulting from the delivery as
from QC Release shall be borne by Bioamber. ARD shall insure that each order complies with the quantities and dates of shipping indicated in the applicable Purchase Order. It is expressly understood that the terms and conditions of this Agreement
along with the quantities of the Product and the dates of shipping indicated in a Purchase Order, will govern the sale of such Product notwithstanding any contradictory, additional or different terms and conditions that may be contained within a
Purchase Order, in an acknowledgement, invoice or receipt or any kind of communication between the parties. 

  

	 	10.2.	The Purchase Orders shall be sent to ARD by email with confirmation of receipt. The Purchase Orders must, in particular, mention the quantity and the date of delivery.

  

	 	10.3.	The delivery dates related to the Purchase Orders are subject to confirmation by ARD, taking into account ARD’s production schedule, work in progress and the
availability of raw material. In the event ARD is not able to respect a delivery date, the parties will agree to a revised delivery date. The Purchase Orders shall be deemed to have been accepted by ARD if it has not made any written reservations in
relation to them within eight (8) business days after the date of the confirmation of receipt of the corresponding email, it being specified that the aforesaid reservations must in any event be formally accepted by Bioamber.

  

	11.	PROPERTY AND RISKS 

  

	 	11.1.	 Title of ownership and the risks involved in the loss of the Product shall be transferred from ARD to Bioamber when the Product have been reviewed by
Bioamber according to the provisions of section 9 and Bioamber is satisfied that such Product meets the Product Specifications and Packaging Specifications. Upon Bioamber’s written notification to ARD that such Product is in accordance with the
Product Specifications and Packaging Specifications, the Product will be released from quarantine. ARD will then affix the seals on the bags in order to prevent any modification of the Product and Bioamber will therefore assume title of ownership as
well as any risk associated with such ownership (“QC Release”). No Product shall leave the warehousing facility within the Demonstration Plant or be delivered to the designated carrier as provided in Section 9.1 prior to having

  
 7 

 * Confidential treatment requested 

	 	
been QC Release and having been closed with seals. Bioamber shall commit to complete the QC process in order to limit as much as possible the level of ARD Products inventory.

  

	12.	REPRESENTATIONS AND WARRANTIES 

  

	 	12.1.	ARD represents and warrants to Bioamber: 

  

	 	12.1.1.	That at the time of the QC Release, ARD will be the sole owner of the Product and that the said Product will be free of any lien, will not be liable to seizure or
garnishment and will not be subject to any right or claim from third parties. That the Products, when delivered to Bioamber, will comply with the Product Specifications, the Packaging Specifications and has been produced in compliance with the
standard operating procedures and master batch records defined in the Work Plan attached to the Transitional Work Plan Agreement in addition to any other requirement, terms and conditions as provided for in this Agreement. 

 

	 	    	Notwithstanding the preceding, in the event that Bioamber imposes a decision that ARD does not agree with related to the Product Specifications, the Packaging
Specifications, the standard operating procedures and/or the master batch records of any Product to be manufactured by ARD in connection with this Agreement, and ARD notifies Bioamber of its objection in writing, indicating the reasons for its
objection, then, if ARD has complied with all applicable standard operating procedures and master batch records and fulfilled its obligations under this Agreement, subject to all applicable laws, ARD shall not have any liability under this section
12.1.1 in the event that the concerned Product, when delivered to Bioamber, does not comply with the Product Specifications or the Packaging Specifications, if such non compliance is the result of the decision imposed by Bioamber.

  

	 	12.1.2.	Subject to the provisions of 12.1.3, that it has obtained all the insurances, permits and authorizations required for the purpose of manufacturing and packaging the
crystalline succinic acid as required by law subject to any assistance Bioamber might provide with this respect. 

  

	 	12.1.3.	With respect to REACH, all costs related to registration shall be borne by Bioamber, but ARD will provide any reasonable assistance to Bioamber in connection with such
registration; 

  

	 	12.1.4.	That it has all the powers as required by law to sign this Agreement, to exercise its own rights and to comply with the obligations resulting from this Agreement, and
is not a party to any contract whereby it would be prohibited from being a party to this Agreement. 

  
 8 

 * Confidential treatment requested 

	 	12.2.	Bioamber represents and warrants to ARD that it has all the powers as required by law and has determined with appropriate legal assistance that it is authorized to sign
this Agreement, to exercise its own rights and to comply with the obligations resulting from this Agreement, and is not a party to any contract whereby it would be prohibited from being a party to this Agreement. 

 

	13.	INDEMNITY 

  

	 	13.1.	ARD shall hold Bioamber free of any direct damage, costs (including reasonable legal and adjustment costs), losses and claims that Bioamber would have to pay relating,
directly to: 

  

	 	13.1.1.	The failure by ARD to fulfill or meet any obligation, engagement, representation or warranty as stipulated in this Agreement. 

For the avoidance of doubt, this article 13 does not apply to any claim made pursuant to 9.2 when ARD has remedied the reservation and
claims made by Bioamber in accordance with section 9.2 of this Agreement. 
  

	 	13.1.2.	Any direct damages or material losses resulting from any Product ARD produces which is not in compliance with the standard operating procedures and master batch records
defined in the Work Plan attached to the Transitional Work Plan Agreement or resulting from gross negligence on the part of ARD or the obvious failure of ARD to comply with the Product Specifications or the Packaging Specifications at the time such
Product was produced. 

 No party shall, in any case, be liable to the other party for any indirect
consequential, consecutive, pecuniary and/or punitive damages suffered by such other party upon execution of the Agreement. 
  

	 	13.1.3.	The amount of the indemnification for which ARD may be liable with respect to any damage suffered by Bioamber will be calculated after deducting, if any, the amount of
any benefit received by Bioamber from an insurance company on direct account of the damages giving rise to the claim. 

 The amount of the indemnification for which ARD may be liable with respect to any damage suffered by Bioamber will be calculated after deducting, if any, the amount of the benefit resulting from an
immediate tax savings benefiting to Bioamber as a result of the tax deductibility of said damages. 
  

	 	13.1.4.	ARD shall not be liable under this Article 13 unless a Claim Notice has been given at the latest by the first anniversary date following the occurrence date of the
event giving rise to the Claim under this Section 13 at which this Agreement is terminated. 

  
 9 

 * Confidential treatment requested 

	 	    	Bioamber may give notice of a Claim against ARD under this Article 13 (a “Claim Notice”) during the applicable claim period set out in this article
13.1.4. 

 Once Bioamber has become aware of events that are likely to give rise to Claims under this article 13,
Bioamber must give notice of such Claims within 20 (twenty) Business Days from the date at which Bioamber has become aware of the events that were likely to give rise to such Claim. Failure to provide such Claim Notice within such time period will
not operate to relieve ARD of any liability for such claim. 
 ARD shall be deemed to accept any Claim made by Bioamber and
shall be liable to indemnify Bioamber Party for the amount of damages requested in such Claim (subject to the limitations set out in this article 13) unless ARD have given Bioamber a notice within 30 days following the Claim Notice substantially
evidencing that ARD is not in breach. For the avoidance of doubt, shall ARD not reply within 30 days, this lack of reply shall be regarded as an acceptance of the Claim by ARD. If the notice to Bioamber following the Claim Notice is not given within
30 days or if said notice does not substantially evidence that ARD is not in breach, Bioamber shall be entitled to ask to ARD for payment of the indemnities within twenty (20) business days as from the expiration of the above 30-day period.

 Parties shall in good faith discuss any and all Claims with a view to reaching agreement on whether and to what extent ARD
is liable for the damage. 
 If ARD and Bioamber are unable to reach agreement within a period of two (2) months on the
amount of the damage to be indemnified by ARD, the matter may be referred to arbitration. 
  

	 	13.1.5.	The liability cap for ARD under this Article 13 shall be limited, for each Purchase Order, to the amount of the Purchase Order paid by Bioamber to ARD and, annually, to
20 % of the turn-over excluding taxes realised by ARD with Bioamber, excluding any situation of gross negligence or wilful misconduct on the part of ARD. 

 

	 	13.2.	Bioamber shall hold ARD free of any direct damage, costs (including reasonable legal and adjustment costs) or losses and claims that ARD would have to pay relating
directly to: 

  

	 	13.2.1.	The failure by Bioamber to fulfill or meet any obligation, engagement, representation or warranty as stipulated in this Agreement; 

  
 10 

 * Confidential treatment requested 

	 	13.2.2.	Any bodily injury (including death) or moral prejudice sustained by a person and/or any damages or material losses in connection with the Product resulting from gross
negligence on the part of Bioamber. 

  

	 	13.2.3.	The provisions of the above subsections 13.1.3 to 13.1.5 shall apply to this section 13.2, mutatis mutandis. 

 

	14.	RECALL OF THE PRODUCT 

  

	 	14.1	In the event of a recall of the Product initiated by Bioamber, whether voluntarily or because of an order from competent authorities, Bioamber shall be solely
responsible for the organization, execution and costs of the recall unless ARD’s gross negligence is demonstrated, in which case ARD shall be solely responsible for the organization, execution and costs of the recall. In case of a shared
responsibility so declared by an expert, such responsibility shall be borne by each party in its relevant proportion. 

  

	15.	INSPECTION, RECORDS 

  

	 	15.1.	Bioamber, its representatives or agents shall have the right to visit, with a prior notice of three (3) business days and subject to the approval of ARD, which
approval shall not be unreasonably withheld, the installations of ARD in relation to the manufacturing of the Product to make sure that the Product is manufactured according to the terms and conditions of this Agreement. Samples can be taken from
time to time for the purpose of laboratory evaluation independently of the Demonstration Plant and ARD analytical labs. Such independent analyses will be paid solely by Bioamber. 

 

	 	15.2.	ARD will keep records for at least five (5) years showing the Product manufactured pursuant to this Agreement. ARD will permit Bioamber, its representatives or
agents to obtain a copy of such records. 

  

	16.	TERM 

  

	 	16.1	This Agreement shall automatically enter into force from the date that the Steering Committee, created in accordance with the Transitional Work Plan Agreement, has
agreed to according to the section 2.2 of the Transitional Work Plan Agreement, and shall remain in effect until June 30, 2013, unless earlier terminated in accordance with other provisions of this Agreement or unless prorogated by the parties.

  

	17.	TERMINATION 

  

	 	17.1	This Agreement may be terminated as provided below, upon the occurrence of any of the following events: 

  
 11 

 * Confidential treatment requested 

	 	17.1.1.	 If the cumulative levels of the usage factors required for the production of crystalline succinic acid remain higher, after June 30th, 2011, than the Target Usage Factors listed in Schedule Y upon
execution by the Parties, Bioamber may solely terminate this Agreement without damages by giving written notice to this effect to ARD. 

  

	 	17.1.2.	If a party to this Agreement becomes insolvent, assigns its assets to its creditors, initiates a liquidation of its assets, files for bankruptcy or if a petition for
bankruptcy is filed against it, the other party may immediately terminate this Agreement. 

  

	 	17.1.3.	ARD, Bioamber and DNP Green hereby agree that ARD shall be entitled to terminate, immediately and without damages, this Agreement in case the validity, patentability,
enforceability and/or non-infringement of the IP which is licensed by Bioamber and/or DNP Green to ARD to perform this Agreement, is challenged by a third party non-affiliated with ARD or any of its Affiliates and that a final judgment is issued by
a court confirming such third party’s allegation of infringement. 

  

	 	    	DNP Green, Bioamber and their Affiliates hereby agree to hold harmless and indemnify ARD, ARD’s direct and indirect subsidiaries, affiliated entities and
corporations, against any and all damages, liabilities, losses, costs and expenses (including attorneys’ fees and expenses), arising out of any above mentioned challenge of the IP which is licensed by Bioamber and/or DNP Green to ARD to
enable ARD to perform this Agreement. 

  

	 	17.1.4.	If a party infringes or fails to respect any of the terms, clauses, conditions or stipulations of this Agreement, the other party may terminate this Agreement by giving
written notice of such default and provided that such default has not been cured within thirty (30) days from receipt of the notice. 

  

	18.	OBLIGATION OF THE PARTIES AT THE TERMINATION OF THEAGREEMENT 

 Following the termination of this Agreement: 
  

	 	18.1.	ARD shall finish in an expeditious manner any Purchase Order in which the manufacturing, processing and/or packaging of the Product has begun. After completion of any
such order, ARD will stop all such manufacture, processing and/or packaging of the Product. 

  

	 	18.2.	Bioamber will pay to ARD all Purchase Orders that have been completed and delivered to Bioamber or its customers, under reserve of the rights of Bioamber as provided
for in Section 9.2. 

  
 12 

 * Confidential treatment requested 

	 	18.3.	ARD will immediately deliver to Bioamber, at the latter’s cost, all the QC Release Product in inventory, any in process materials related to the Product and all
Bioamber Packing Materials. 

  

	19.	INSURANCE 

 ARD
and Bioamber shall, and shall cause their respective Affiliates to, have and maintain such type and amounts of liability insurance covering the performance of this Agreement as it is normal and customary in this industry generally for parties
similarly situated, and shall upon request provide the other Party with a coverage certificate in that regard, along with any amendments and revisions thereto. 
  

	20.	RESEARCH AND DEVELOPMENT / INTELLECTUAL PROPERTY 

  

	 	20.1.	ARD acknowledges that all work, receipts, specifications, lists of ingredients, reports, documents, improvements or other original works relating directly or indirectly
to the Bioamber Technology and the Products, as well as all intellectual property rights and trade secrets related to the Bioamber Technology and the Products, are the exclusive property of Bioamber. ARD agrees expressly to abstain from claiming
rights with regards to the intellectual property, including, but not limited to, moral rights whenever applicable, and to abstain from using such property, including, but not limited to, all trade secrets, process improvements and process
modifications developed by either party over the term of this Agreement, without written authorization from Bioamber. 

  

	 	20.2.	ARD acknowledges and agrees that Bioamber shall be the owner of all improvements, modifications and applications to and of the Bioamber Technology and the Products
developed by ARD (the “ARD Improvements”) only to the extent that they relate to succinic acid, including, but not limited to the right to file any patent on such ARD Improvements. During the term of this Agreement, ARD shall be
granted a non-exclusive, worldwide royalty-free license to all ARD Improvements, solely for the purposes of this Agreement, and ARD shall be granted a non-exclusive, worldwide royalty free license to any and all ARD Improvements outside the field of
succinic acid. ARD shall provide to Bioamber a written notice of all ARD Improvements, in such detail as Bioamber may reasonably request. Upon termination or expiration of this Agreement, the license granted to ARD pursuant to this Section 20.2
shall terminate immediately. 

  

	 	20.3.	Undertakings and covenants of Bioamber with respect to any intellectual property rights required for the performance of this Agreement granted under this Agreement.

 20.3.1. Bioamber and DNP or any of the successors of their business shall grant to ARD a non-exclusive,
worldwide, free license to any intellectual property rights (“IP”) required for ARD to perform this Agreement. 

  
 13 

 * Confidential treatment requested 

 20.3.2. Warranties: 

Subject to sections below, BIOAMBER AGREES TO DEFEND, INDEMNIFY AND HOLD ARD HARMLESS FROM AND AGAINST ANY AND ALL OUT-OF-POCKET COSTS,
DAMAGES AND LOSSES (INCLUDING WITHOUT LIMITATION REASONABLE ATTORNEY’S FEES AND COSTS) ARISING OUT OF OR RESULTING FROM THIRD PARTY CLAIMS BASED ON ALLEGED INFRINGMENT OF ANY OF THE BIOAMBER’S INTELLECTUAL PROPERTY LICENSED TO ARD PURSUANT
TO SECTION 20.3.1 HEREOF INCLUDING THE CONSEQUENCES TRIGERRED BY THE CONSEQUENT TERMINATION OF THE AGREEMENT. 
 SPECIAL
DAMAGES. EXCEPT IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS AFFILIATES , NEITHER PARTY SHALL BE RESPONSIBLE TO THE OTHER FOR SPECIAL, INCIDENTAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES THAT MAY BE INCURRED PURSUANT
TO THIS AGREEMENT OR PERFORMANCE HEREUNDER. 
 HEALTH AND SAFETY. BIOAMBER WARRANTS OR GUARANTEES THAT THE EXERCISE OF THE
RIGHTS GRANTED PURSUANT TO THIS AGREEMENT AND THE USE OF ANY PRODUCTS MADE PURSUANT TO THE PRACTICE OF SUCH RIGHTS WILL NOT RESULT IN SAFETY OR HEALTH HAZARDS TO WORKERS, THE ENVIRONMENT, OR TO PURCHASERS OF SUCH PRODUCTS. 

INDEMNIFICATION BY BIOAMBER. SUBJECT TO ARD LIABILITY AS MANUFACTURER ON BEHALF OF BIOAMBER AND UNDER BIOAMBER INSTRUCTIONS, BIOAMBER
HAS SOLE DISCRETION AND RESPONSIBILITY FOR ITS DESIGN, MAKING, MANUFACTURE, AND SALE OF PRODUCTS PURSUANT TO THIS AGREEMENT. ACCORDINGLY, TO THE EXTENT PERMITTED BY THE LAW OF FRANCE, OR ANY OTHER LAW APPLICABLE, BIOAMBER SHALL INDEMNIFY, DEFEND,
AND HOLD ARD AND ITS AFFILATES HARMLESS FROM AND AGAINST ANY AND ALL CLAIMS, SUITS, OBLIGATIONS, CAUSES OF ACTION, LIABILITY, COSTS AND DAMAGES (INCLUDING, WITHOUT LIMITATION, ALL CLAIMS, AWARDS FOR DAMAGES, ATTORNEY FEES, COURT COSTS, INTEREST,
PENALTIES, ETC), INJURIES TO PERSONS (INCLUDING DEATH) OR PROPERTY (INCLUDING, WITHOUT LIMITATION, LOSS OF USE), PRODUCT LIABILITY CLAIMS, CLAIMS FOR IP INFRINGEMENT AND CLAIMS FOR DAMAGE TO THE ENVIRONMENT (COLLECTIVELY, “LIABILITIES”),
WHATEVER THE CAUSE MAY BE, BASED UPON, ARISING OUT OF, OR RELATED TO THE ACTS OR OMISSIONS OF BIOAMBER AND ITS AFFILIATES AND/OR ANY OF THEIR EMPLOYEES, OFFICERS, EMPLOYEES, AND CONSULTANTS, SUBLICENSEES OR OTHER PERSONS ACTING ON THEIR BEHALF OR
UNDER THEIR CONTROL, IN CONNECTION WITH BIOAMBER’S EXECUTION, 

  
 14 

 * Confidential treatment requested 

 
DELIVERY AND PERFORMANCE OF, OR FAILURE TO PERFORM, THIS AGREEMENT, EXCLUDING LIABILITIES ARISING OUT OF THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF ARD, SUCH LIABILITIES HAVING BEEN OR NOT
ESTABLISHED IN A COURT OF LAW AS HAVING BEEN CAUSED SOLELY AND DIRECTLY BY THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT ON THE PART OF ARD. 
 INDEMNIFICATION BY ARD. TO THE EXTENT PERMITTED BY THE LAW OF FRANCE, OR ANY OTHER LAW APPLICABLE, ARD SHALL INDEMNIFY, DEFEND, AND HOLD BIOAMBER AND ITS AFFILATES HARMLESS FROM AND AGAINST ANY AND ALL
CLAIMS, SUITS, OBLIGATIONS, CAUSES OF ACTION, LIABILITY, COSTS AND DAMAGES (INCLUDING, WITHOUT LIMITATION, ALL CLAIMS, AWARDS FOR DAMAGES, ATTORNEY FEES, COURT COSTS, INTEREST, PENALTIES, ETC), INJURIES TO PERSONS (INCLUDING DEATH) OR PROPERTY
(INCLUDING, WITHOUT LIMITATION, LOSS OF USE), AND CLAIMS FOR DAMAGE TO THE ENVIRONMENT (COLLECTIVELY, “LIABILITIES”), WHATEVER THE CAUSE MAY BE, BASED UPON, ARISING OUT OF, OR RELATED TO THE ACTS OR OMISSIONS OF ARD AND ITS AFFILIATES
AND/OR ANY OF THEIR EMPLOYEES, OFFICERS, EMPLOYEES, AND CONSULTANTS, SUBLICENSEES OR OTHER PERSONS ACTING ON THEIR BEHALF OR UNDER THEIR CONTROL, IN CONNECTION WITH ARD’S EXECUTION, DELIVERY AND PERFORMANCE OF, OR FAILURE TO PERFORM, THIS
AGREEMENT, NAMELY IN CONNECTION WITH ARD’S MANUFACTURE OF PRODUCTS PURSUANT TO THE TERMS OF THIS AGREEMENT, EXCLUDING LIABILITIES ARISING OUT OF THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF BIOAMBER, SUCH LIABILITIES HAVING BEEN OR NOT
ESTABLISHED IN A COURT OF LAW AS HAVING BEEN CAUSED SOLELY AND DIRECTLY BY THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT ON THE PART OF BIOAMBER. 
  

	 	21.	CONFIDENTIALITY 

  

	 	21.1	 The parties hereby agree to treat the transactions contemplated hereby and all information received in connection therewith in the strictest confidence
and more particularly, ARD hereby agrees to comply will all provisions of the Confidentiality and Non-competition Agreement signed by ARD and effective as of July 1st, 2010, and DNP Green hereby agrees to comply will all provisions of the Confidentiality Agreement signed by DNP Green
and effective as of July 1st, 2010.

  
 15 

 * Confidential treatment requested 

	22.	GENERAL PROVISIONS 

  

	 	22.1	Entire Agreement. This Agreement, together with its schedules W, X, Y and Z, constitutes the entire agreement between the parties hereto with respect to the
subject matter hereof and cancels and supersedes any prior understanding or agreement between the parties hereto with respect to the subject matter hereof. 

 

	 	22.2	Further Assurances. Each party shall at any time and from time to time, upon the request of the other party(ies), execute and deliver such further
documents and do such further acts and things as the other party(ies) may reasonably request to evidence, carry out and give full effect to the terms, conditions, intent and meaning of this Agreement. 

 

	 	22.3	Headings. The section and paragraph headings contained in this Agreement are for the purposes of convenience only and are not intended to define or limit the
content of any section or paragraph. 

  

	 	22.4	Notice. Any notice pursuant to this Agreement shall be in writing and shall be deemed given (a) if by hand delivery, upon receipt thereof, (b) if by
facsimile transmission, upon electronic confirmation thereof, (c) if by electronic mail, upon receipt of confirmation electronic mail message, if promptly followed by a confirmation copy registered mail, return receipt requested, or (d) if
by internationally recognized courier delivery service (such as Federal Express), upon such delivery. All notices shall be addressed (or such other address as either Party may in the future specify in writing to the other) to each concerned party at
the addresses mentioned below: 

  

	 	22.4.1	for ARD: 

      [***]

      Agro Industrie Recherches et Développements, S.A. 

      [***] 

      With a copy to: 

      [***] 

 

	 	22.4.2	forBioamber: 

       Mr. Jean-François Huc, Directeur Général 

      Bioamber S.A.S. 

      1250 Rene-Levesque West, Suite 4110 

      Montreal, Quebec, Canada 

      H3B 4W8 

      E-Mail: [***] 

      Fax: [***] 

  
 16 

 * Confidential treatment requested 

       With a copy to: 

      [***] 

      Boivin Desbiens Senécal, g.p. 

      [***] 

 

	 	22.5	Assignment. ARD and Bioamber may assign their rights or their obligations in this Agreement without the prior written consent of Bioamber or ARD, as applicable,
provided that (a) ARD or Bioamber is in position to evidence in a satisfactory manner to ARD or Bioamber, as applicable, that (i) the beneficiary of the rights and obligations has the financial capacity to fully comply with all the terms
of this Agreement as they apply to ARD, (ii) the beneficiary is not a, direct or indirect, competitor of ARD or of Bioamber and that (iii) the third party shall be bound by all the conditions, covenants and warranties of the Agreementand
(b) ARD is in position to evidence in a satisfactory manner to Bioamber that the beneficiary of the rights and obligations has the ability to produce the Products and comply with the terms of this agreement. 

 

	 	22.6	Schedule and Preliminary Statements. The Preliminary Statements are hereby fully incorporated herein by this reference. 

 

	 	22.7	Amendment. No modification of or amendment to this Agreement shall be valid or binding unless set forth in writing and duly executed by all parties
hereto. 

  

	 	22.8	Costs and Expenses. Each party shall bear its own costs and expenses in connection with the negotiation of this Agreement and the transactions
contemplated by this Agreement. 

  

	 	22.9	Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of France and the courts of France, in the district of
Paris shall have exclusive jurisdiction. 

  

	 	22.10	Publicity. Press Releases, Disclosures and Public Announcements. Each party hereby undertakes not to issue any press release or other publicity materials, or
make any public presentation with respect to the terms or conditions of this Agreement without the prior written consent of the other parties (such consent not to be unreasonably withheld or delayed). 

 

	 	22.11	Specific Performance. The parties hereof acknowledge that monetary damages may not be an adequate remedy for violations of this Agreement and that any party may,
in its sole discretion, in a court of competent jurisdiction, apply for specific performance or injunctive or other relief as the court may deem just and proper in order to enforce this Agreement or to prevent violation hereof. To the extent
permitted by applicable law, each party waives any objection to the imposition of such relief. 

  
 17 

 * Confidential treatment requested 

	 	22.12	Counterparts. This Agreement may be executed by the parties hereto in separate counterparts, each of which when so executed and delivered shall be an
original, but all such counterparts shall together constitute one in the same instrument. This Agreement and all other agreements, certificates, documents and instruments furnished in connection herewith or therewith may be delivered by means of an
exchange of executed documents by facsimile or as an attachment in “pdf” or similar format to an electronic mail message. 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed as of September 30th, 2010. 
  

			
	AGRO INDUSTRIE RECHERCHES ET DÉVELOPPEMENTS S.A.
		
		 	/s/ [***]
		 	By: [***]
		 	Title: [***]
	
	BIOAMBER S.A.S.
		
		 	/s/ Jean- François Huc
		 	 By: Jean-François Huc

Title: Directeur Général

	
	DNP GREEN TECHNOLOGY, INC.
		
		 	/s/ Jean- François Huc
		 	 By : Jean-François Huc
 Title: President

  
 18 

 * Confidential treatment requested 

 SCHEDULE W 
 PRODUCT SPECIFICATIONS 
 [***] 

  
 19 

 * Confidential treatment requested 

 SCHEDULE X 
 QUALITY STANDARDS 
 [***] 

  
 20 

 * Confidential treatment requested 

 SCHEDULE Y 
 TARGET USAGE FACTORS 
 [***] 

  
 21 

 * Confidential treatment requested 

 SCHEDULE Y.2 
 [***] 

  
 22 

 * Confidential treatment requested 

 SCHEDULE Z 
 LABOR COSTS 
 [***] 

  
 23 

 * Confidential treatment requested 

 AMENDMENT TO THE TOLL MANUFACTURING AGREEMENT ENTERED INTO 

BETWEEN AGRO INDUSTRIE RECHERCHES ET DÉVELOPPEMENTS, S.A., 

BIOAMBER S.A.S. AND DNP GREEN TECHNOLOGY, INC. 

AS OF SEPTEMBER 30TH, 2010 
 This Amendment Agreement is made as of December 17th, 2010, between Agro Industrie Recherches et Développements, S.A. (“ARD”), BioAmber S.A.S. (“BioAmber France”) and BioAmber Inc. (formerly known as DNP Green Technology, Inc.)
(“BioAmber US”). 
 WHEREAS ARD, BioAmber France and BioAmber US entered into a Toll Manufacturing Agreement as of
September 30th, 2010 (the “Agreement”);

 WHEREAS DNP Green Technology, Inc. changed its name to “BioAmber Inc.” as of November 16th, 2010; 
 WHEREAS the parties agree to amend the Agreement as set forth herein; 
 NOW THEREFORE, THE
PARTIES AGREE AS FOLLOWS: 
  

	1.	The Agreement is modified in the following manner, the provisions of the Agreement not modified herein shall continue to be in force as stated in the Agreement:

  

	 	1.1.	The following subsection 16.2 is added to the Agreement: 

  

	 	“16.2	 This Agreement shall be renewable, at the option of Bioamber, for three (3) successive periods of six (6) months (each, a “Renewal
Option”), being from July 1st, 2013 until
December 31st, 2013, from January 1st, 2014 until June 30th, 2014 and from July 1st, 2014 until December 31st, 2014 (each, a “Renewed Term”).

 In order to exercise a Renewal Option, BioAmber France shall notify ARD accordingly, in writing, [***]
prior to the beginning of the applicable Renewed Term relating to the Renewal Option being exercised. 
 The terms and
conditions applicable during each Renewed Term shall be identical to those applicable during the initial term of this Agreement, except for the following: 
  

	 	(i)	Bioamber shall only benefit of 60 % of the total production capacity of the Demonstration Plant during each Renewed Term, and shall therefore not pay more than
60 % of the labor costs associated with the operation of the Demonstration Plant during such period; 

  

	 	(ii)	 for each Renewal Option exercised, Bioamber shall pay to ARD an aggregate sum of [***] in order to compensate ARD for the depreciation costs incurred
related to the Demonstration Plant during 

  
 1 

 * Confidential treatment requested 

	 	
each Renewed Term, which sum shall be payable in six (6) equal and consecutive monthly instalments of [***] during each Renewed Term.” 

IN WITNESS WHEREOF, THE PARTIES HERETO HAVE SIGNED THIS AGREEMENT AS OF THE DATE FIRST WRITTEN ABOVE. 

 

	
	AGRO INDUSTRIE RECHERCHES ET DÉVELOPPEMENTS S.A.
	
	/s/ [***]            
	By: [***]
	Title: [***]

  

	
	BIOAMBER S.A.S.
	
	/s/ Jean-François Huc             
	By: Jean-François Huc
	Title: President

  

	
	BIOAMBER INC.
	
	/s/ Jean-François Huc             
	By : Jean-François Huc
	Title: President

  
 2 

 * Confidential treatment requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}]]